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In an era of widespread antibiotic resistance, basidiomycete fungi are a useful 
source of possible antimicrobials, with pleuromutilin being one of them. Due to its 
mechanism of action which comprises the binding of the conserved peptidyl 
transferase centre, resistance to pleuromutilin is slow to be developed and has 
minimal cross-resistance with other antibiotics. The pleuromutilin biosynthetic gene 
cluster and pathway of chemical intermediates is known, and its heterologous 
expression has been achieved in fungi. This thesis reports attempts to express parts of 
the pleuromutilin pathway in different plant hosts, including Marchantia polymorpha 
and Nicotiana tabacum. Prior to genetic engineering of the hosts, this work shows that 
pleuromutilin, mutilin and a diverse selection of antibiotics impact on growth and 
morphology of Physcomitrella patens and M. polymorpha, when supplemented into 
growing media, indeed the pleuromutilin derivative, tiamulin led to inhibition of 
growth of P. patens and M. polymorpha.  
The construction of multigene expression plasmids using Golden Gate 
technology is described. Transient expression was performed in N. tabacum and 
stable transformants obtained in M. polymorpha. Expression analysis using qPCR was 
carried out to validate the heterologous expression of the genes. The results from 
HPLC analysis were unclear and did not prove the presence of pleuromutilin 
metabolic intermediates, indicating that more work is needed to fine-tune the 



















First of all, I am grateful to Prof Gary Foster and Dr Andy Bailey for giving 
me the opportunity to work in their research group, as well as their mentoring during 
my studies. Their guidance and constant encouragement played a major role in my 
aspiration of continuing doing research.  
I have been really fortunate to work in a wonderful environment, and I cannot 
thank enough all the members of Lab321, especially Dr Ian Prosser, Dr Katherine 
Williams, Dr Amy James and the PhD student Helen Rees for every valuable advice 
inside and outside the lab. Also, my sincere thanks to Dr Jill Harrison and PhD 
student Zoe Nemec Venza for their help in plant propagation and transformation. 
Last but not least, I would like to thank my family, my partner and close 
friends, being always there to support me in their way, while trying to understand with 

























The unprecedented situation of the Covid-19 lockdown had a significant impact on 
my research project. The lockdown prevented the production and testing of additional 
transformants of Marchantia polymorpha or any repeats of the HPLC and qPCR 
analyses. Furthermore, transformation of Physcomitrella patens and further analysis 
of any stable transformants could not proceed. Last but not least, thesis writing was 






























I declare that the work in this dissertation was carried out in accordance with 
the requirements of the University's Regulations and Code of Practice for Research 
Degree Programmes and that it has not been submitted for any other academic award. 
Except where indicated by specific reference in the text, the work is the candidate's 
own work. Work done in collaboration with, or with the assistance of, others, is 
indicated as such. Any views expressed in the dissertation are those of the author. 
















Abstract ......................................................................................................................... 3 
Acknowledgements ...................................................................................................... 5 
COVID-19 statement ................................................................................................... 7 
Author’s declaration ..................................................................................................... 9 
List of Figures ............................................................................................................. 13 
List of Tables .............................................................................................................. 16 
List of Abbreviations ................................................................................................. 17 
Chapter 1: Introduction ............................................................................................ 21 
1.1 From traditional medicine to drug discovery ..................................................... 21 
1.2 Bioactive natural products from fungi ............................................................... 21 
1.2.1 Using filamentous fungi as heterologous platforms ........................................ 24 
1.2.2 From gene clusters to biosynthetic pathways .................................................. 26 
1.3 An introduction to pleuromutilins and their clinical potential ........................... 28 
1.3.1 Isolation, origin and mechanism of action ...................................................... 29 
1.3.2 Early studies of structure and biosynthesis of pleuromutilin .......................... 30 
1.3.3 Chemical Synthesis of pleuromutilins ............................................................. 31 
1.3.4 Recent identification of pleuromutilin gene cluster ........................................ 32 
1.3.5 Enhancement of pleuromutilin production ...................................................... 34 
1.3.5.1 Attempted overexpression in the native host C. passeckerianus ............. 34 
1.3.5.2 Successful heterologous expression in Aspergillus oryzae ...................... 35 
1.3.6 Pleuromutilin derivatives and clinical potential .............................................. 35 
1.4 Plants as biosynthetic machinery for secondary metabolites ............................. 37 
1.4.1 A moss-based expression platform ................................................................. 37 
1.4.1.1 Methods and approaches in moss genetic engineering ............................. 38 
1.4.2 Liverworts in biotechnology ........................................................................... 40 
1.4.2.1 Tools and techniques for Marchantia research ........................................ 42 
1.4.3 Nicotiana species for biopharmaceutical production ...................................... 45 
1.5 Aims of this project ............................................................................................ 46 
Chapter 2: Materials and Methods .......................................................................... 47 
2.1 Laboratory supplies ............................................................................................ 47 
2.2 Species used in this project ................................................................................ 47 
2.2.1 Bacterial Species, growth and maintenance ................................................ 47 
2.2.2 Plant Species, growth and propagation........................................................ 49 
11 
 
2.3 Antibiotic treatment assays ................................................................................ 50 
2.4 Construction of plasmids .................................................................................... 52 
2.4.1 Modular Cloning (MoClo) using the Golden Gate® assembly ................... 52 
2.4.2 Level generations ......................................................................................... 53 
2.4.2.1 Level -1 ..................................................................................................... 54 
2.4.2.2 Level 0 ...................................................................................................... 54 
2.4.2.3 Level 1 ...................................................................................................... 54 
2.4.2.4 Level 2 ...................................................................................................... 55 
2.4.2.5 Level M and Level P ................................................................................ 56 
2.4.3 One pot digestion-ligation reaction ...................................................... 57 
2.4.4 Expression cassettes design schemes .......................................................... 62 
2.5 Molecular Techniques ........................................................................................ 68 
2.5.1 DNA extraction............................................................................................ 68 
2.5.2 RNA extraction ............................................................................................ 69 
2.5.3 DNase treatment .......................................................................................... 70 
2.5.4 Plasmid extraction ....................................................................................... 71 
2.5.4.1 E. coli small-scale plasmid extraction ...................................................... 71 
2.5.4.2 E. coli alkaline lysis small-scale plasmid extraction ................................ 71 
2.5.4.3 E. coli large-scale plasmid extraction ....................................................... 72 
2.5.4.4 A. tumefaciens plasmid extraction ............................................................ 72 
2.5.5 Restriction Digest ........................................................................................ 73 
2.5.6 Polymerase Chain Reaction (PCR) .............................................................. 74 
2.5.7 Quantitative Reverse Transcription PCR (RT-qPCR) ................................. 77 
2.5.8 Gel electrophoresis ...................................................................................... 81 
2.5.9 PCR product purification ............................................................................. 82 
2.5.10 Gel extraction ............................................................................................ 82 
2.5.11 DNA sequencing........................................................................................ 82 
2.5.12 Quantification of nucleic acids .................................................................. 83 
2.6 Preparation of competent bacterial cells ............................................................ 83 
2.6.1 Chemically competent E.coli ....................................................................... 83 
2.6.2 Electro-competent E. coli ............................................................................ 84 
2.6.3 Chemically competent A. tumefaciens ......................................................... 85 
2.6.4 Electro-competent A. tumefaciens ............................................................... 85 
12 
 
2.7 Transformation of bacterial cells ........................................................................ 86 
2.7.1 Chemical transformation of E.coli ............................................................... 86 
2.7.2 Electroporation of E. coli ............................................................................. 86 
2.7.3 Chemical transformation of A. tumefaciens ................................................ 87 
2.7.4 Electroporation of A. tumefaciens ............................................................... 87 
2.8 Agro-infiltration of Nicotiana tabacum (Li, 2011) ............................................ 87 
2.9 Stable transformation of Marchantia polymorpha ............................................. 88 
2.10 Stable transformation of Physcomitrella patens (Schaefer et al., 1991) .......... 91 
2.11 Metabolite extraction from plant material ........................................................ 94 
2.12 LCMS analysis ................................................................................................. 94 
2.13 Bioinformatics software ................................................................................... 95 
2.14 Microscopic observation and image processing ............................................... 95 
Chapter 3: Construction of plasmids ....................................................................... 96 
3.1 Aims ................................................................................................................... 96 
3.1.1 Level 0 plasmids .......................................................................................... 96 
3.1.2 Level 1 plasmids .......................................................................................... 97 
3.1.3 Level 2, M and P plasmids ........................................................................ 101 
Chapter 4: Assessing host-plant sensitivity to mutilins and other antibiotics .... 112 
4.1 Aims ................................................................................................................. 112 
4.1.1 Effect of antibiotics on growth of P. patens and M. polymorpha ............. 112 
4.1.2 Effect of antibiotics on the morphology of P. patens and M. polymorpha 121 
Chapter 5: Heterologous plant hosts for expression of the pleuromutilin 
biosynthetic pathway ............................................................................................... 124 
5.1 Aim ................................................................................................................... 124 
5.1.1 Agrobacterium-infiltration of tobacco led to chlorotic leaves ................... 124 
5.1.2 HPLC analysis of extracts from infiltrated leaves ..................................... 126 
5.2.1 Marchantia transformation using cut thalli ............................................... 128 
5.2.2 HPLC analysis of Marchantia tissue ......................................................... 130 
5.2.3 Expression analysis of the genes under study in M. polymorpha .............. 133 
Chapter 6: Discussion and Further work .............................................................. 140 
6.1 Antibiotic assays .............................................................................................. 141 
6.2 The suitability of the heterologous host ........................................................... 143 
6.3 Agrobacterium-infiltration of tobacco ............................................................. 143 
6.4 M. polymorpha heterologous expression ......................................................... 144 
13 
 
6.5 M. polymorpha HPLC analysis ........................................................................ 145 
6.6 Future work ...................................................................................................... 146 
References ................................................................................................................. 147 
Appendices ................................................................................................................ 165 
Appendix A: Coding sequences of the genes after domestication and plasmid maps 
of Level 0, Level 1, Level 2 ................................................................................... 165 
Appendix B: Antibiotic treatments ........................................................................ 173 
 
List of Figures 
Figure 1.1 Diversity of fungal bioactive natural products ...................................................... 24 
Figure 1.2 A generalised biosynthetic gene cluster. ............................................................... 28 
Figure 1.3 (A) A mature Clitopilus passeckerianus fruiting body. (B) Chemical structure of 
pleuromutilin ........................................................................................................................... 29 
Figure 1.4 (A) Schematic of protein translation. (B) Partial structure of tiamulin and (C) 
retapamulin bound to the 50S ribosomal subunit of D. radiodurans. .......................................... 30 
Figure 1.5 (A) Pleuromutilin BGC (B) Proposed biosynthetic pathway of pleuromutilin. .... 33 
Figure 1.6 Proposed biosynthetic pathway of pleuromutilin .................................................. 34 
Figure 1.7 Clinical and pre-clinical pleuromutilins ................................................................ 36 
Figure 1.8 Physcomitrella patens. .......................................................................................... 38 
Figure 1.9 Life cycle of Marchantia polymorpha. ................................................................. 41 
Figure 1.10 Basic (Level 0) DNA parts in the OpenPlant toolkit ........................................... 44 
Figure 2.1 Hierarchy of the modular cloning system ............................................................. 53 
Figure 2.2 Example of a Level 1 Transcription Unit .............................................................. 55 
Figure 2.3 Relationship between Levels ................................................................................. 56 
Figure 2.4 Map of the Pp108 locus created using SnapGene® ............................................... 63 
Figure 2.5 Modular Cloning (MoClo) for the construction of the plasmids used for M.  
polymorpha and N. tabacum transformation. .......................................................................... 66 
Figure 2.6 Schematic of the modular cloning technique of the plasmids designed for P. 
patens transformation .............................................................................................................. 67 
Figure 2.7 Schematic of the modular cloning technique of the plasmids designed for P. 
patens transformation .............................................................................................................. 68 
Figure 2.8 SYBR Green Dye during amplification ................................................................ 78 
Figure 2.9 Graph of the amplification plot, standard curve and melt curve of th RT-qPCR 
using Luna® kit ....................................................................................................................... 78 
14 
 
Figure 2.10 5μl of 1kb Plus DNA Ladder visualised by ethidium bromide staining on a 1% 
(w/v) TBE agarose gel ............................................................................................................. 82 
Figure 2.11 Transformation of M. polymorpha regenerating thalli. ....................................... 91 
Figure 3.1 Agarose gel (1% w/v) of Level 0 plasmids ........................................................... 97 
Figure 3.2 Plasmids of Level 0 (A) and Level 1 (B) of the ggs gene ..................................... 98 
Figure 3.3 Agarose gel (1% w/v) of Level 1 TU plasmids. .................................................... 99 
Figure 3.4 Agarose gel (1% w/v) of Level 1 35S::gfp::tnos ................................................. 100 
Figure 3.5 Agarose gel (1% w/v) of Level TU vector and Pp108.1 locus amplicons into the
 ............................................................................................................................................... 101 
Figure 3.6 Agarose gel (1% w/v) of Level 2, Level M no6, Level M no7 and end-linker 
pELB4 vectors ....................................................................................................................... 101 
Figure 3.7 Transformation after ligation with Level 2.4 vector, containing the first four genes
 ............................................................................................................................................... 102 
Figure 3.8 E. coli strains DH5α and TOP10, streaked on LB agar plates ............................ 104 
Figure 3.9 Predicted Plasmid maps of Level 2.4_D (A) and Level 2.4_35S (B) ................. 105 
Figure 3.10 Agarose gel (1% w/v) of potential Level 2.4_D and Level 2.4_35S plasmids.. 105 
Figure 3.11 Agarose gel (1% w/v) of Level 1 and plasmids for the first four genes, cut with 
various restriction enzymes ................................................................................................... 106 
Figure 3.12 Agarose gel (1% w/v) of Level 2.3, 2.4 and 2.6 plasmids, cut with various 
restriction enzymes. ............................................................................................................... 107 
Figure 3.13 Agarose gel (1% w/v) of pICH41308, pICSL70004, nptII amplicon, Level 0 and 
Level 1, and initial Level 1 nptII ........................................................................................... 109 
Figure 3.14 Agarose gel (1% w/v) of pL2.2, pL2.5 and pL2.7, all units containing the 35S 
promoter ................................................................................................................................ 111 
Figure 4.1 Tiamulin treatment assay for P. patens (left) and M. polymorpha (right). ......... 114 
Figure 4.2 Tiamulin treatment assay for P. patens (A) and M. polymorpha (B) .................. 114 
Figure 4.3 Mutilin treatment assay for P. patens (left) and M. polymorpha (right) ............. 115 
Figure 4.4 Mutilin treatment assay for P. patens (A) and M. polymorpha (B). ................... 115 
Figure 4.5 Chloramphenicol treatment assay for P. patens (left) and M. polymorpha (right)
 ............................................................................................................................................... 116 
Figure 4.6 Chloramphenicol treatment assay for P. patens (A) and M. polymorpha (B) ..... 117 
Figure 4.7 Kanamycin treatment assay for P. patens (left) and M. polymorpha (right). ...... 117 
Figure 4.8 Kanamycin treatment assay for P. patens (A) and M. polymorpha (B) .............. 118 
Figure 4.9 Nalidixic acid treatment assay for P. patens (left) and M. polymorpha (right) ... 119 
Figure 4.10 Nalidixic acid treatment assay for P. patens (A) and M. polymorpha (B). ....... 119 
Figure 4.11 Ampicillin treatment assay for M. polymorpha. ............................................... 120 
Figure 4.12 Ampicillin treatment assay for M. polymorpha ................................................ 120 
15 
 
Figure 4.13 Developmental effects of antibiotics on P. patens ............................................ 121 
Figure 4.14 Developmental effects of antibiotics on M. polymorpha. ................................. 122 
Figure 4.15 Effects of antibiotics on P. patens protonemata ................................................ 123 
Figure 5.1 Tobacco leaves Agrobacterium-infiltration with the different plasmids, 3, 5 and 7 
days post-infection ................................................................................................................ 125 
Figure 5.2 HPLC analysis of tobacco leaves extracts; extracted ion chromatographs for 289 
(A, B), 366 (C, D) and 423 (E, F, G) in the ES- spectrum .................................................... 127 
Figure 5.3 Time-course observation of Tak-1 WT thalli ...................................................... 128 
Figure 5.4 Marchantia transformation protocol workflow ................................................... 129 
Figure 5.5 Characteristic morphology of Marchantia thalli during transformation ............. 129 
Figure 5.6 HPLC analysis of tobacco leaves extracts for 289 (A, B), 366 (C, D) and 423 (E, 
F, G, H) in the ES- spectrum ................................................................................................. 132 
Figure 5.7 0.8% agarose gel of RNA samples after total RNA purification and genomic DNA 
removal from Marchantia polymorpha ................................................................................. 133 
Figure 5.8 qPCR data analysis of the GGPP synthase gene in control (transformed with an 
empty vector) and transformed with the gene under study (ggs) lines of M. polymorpha. ... 135 
Figure 5.9 qPCR data analysis of the terpene cyclase gene in control (transformed with an 
empty vector) and transformed with the gene under study (cyc) lines of M. polymorpha. ... 135 
Figure 5.10 qPCR data analysis of the cytochrome p450-1 gene in control (transformed with 
an empty vector) and transformed with the gene under study (p450-1) lines of M. polymorpha
 ............................................................................................................................................... 136 
Figure 5.11 qPCR data analysis of the cytochrome p450-2 gene in control (transformed with 
an empty vector) and transformed with the gene under study (p450-2) lines of M. polymorpha
 ............................................................................................................................................... 137 
Figure 5.12 qPCR data analysis of the short-chain reductase gene in control (transformed 
with an empty vector) and transformed with the gene under study (sdr) lines of M. 
polymorpha ............................................................................................................................ 137 
Figure 5.13 qPCR data analysis of the acetyltransferase (left) and cytochrome p450-3 (right) 
genes in control (transformed with an empty vector) and transformed with the genes under 
study (atf or p450-3) lines of M. polymorpha ....................................................................... 138 
Figure 5.14 Summary illustration of the pleuromutilin gene cluster with every M. polymorpha 






List of Tables 
Table 2.1 Antibiotics used for E. coli and A. tumefaciens cells. ............................................. 48 
Table 2.2 Plant media for P.patens and M. polymorpha. ....................................................... 50 
Table 2.3 Antibiotics used for toxicity tests for P. patens and M. polymorpha ..................... 51 
Table 2.4 List of destination and end-linker vectors used from MoClo Plant Tool Kit for 
Golden Gate Assembly ............................................................................................................ 57 
Table 2.5 List of Level 0 vectrors (standard parts) used from Golden Gate Plant Parts Kit for 
Golden Gate Assembly ............................................................................................................ 58 
Table 2.6 Primers used for amplification of approximately 1kb of Pp108 neutral locus from 
the P. patens genome ............................................................................................................... 62 
Table 2.7 Primers used for amplification of the new nptII coding sequence .......................... 63 
Table 2.8 Diversity of promoters and terminators used in multigene constructs ................... 67 
Table 2.9 Extraction Buffer used for CTAB DNA extraction method ................................... 69 
Table 2.10 Restriction enzymes used in digest for screening of the plasmids isolated .......... 73 
Table 2.11 Primers used for amplification of a fragment of the genes ................................... 75 
Table 2.12 Primers used for qPCR and sequencing ................................................................ 80 
Table 2.13 Primers used for amplification of the old nptII Level 1 transcription unit. .......... 82 
Table 2.14 0M51C medium used for M. polymorpha transformation .................................... 89 
Table 2.15 Solutions used for the PEG-mediated transformation of P. patens protoplasts…93 
Table 3.1 Final plasmids made and used in transformation of M. polymorpha and Agro-
infiltration of tobacco………………………………………………………………………..111 
Table 5.1 Different groups/ lines of M. polymorpha transformed with individual constructs 










List of Abbreviations 
 
(w/v) Weight/Volume 
°C Degree Celcius 
35S/CaMV 35S Cauliflower mosaic virus 35S promoter 
Act2 Actin 2 
AlK(SO4)2 Aluminum potassium sulfate 
AT di-ammonium tartrate 
atf Acetyltransferase gene 
ATP Adenosine triphosphate 
BGC Biosynthetic gene cluster 
BLAST Basic local alignment search tool 
bp Base pairs 
Ca(NO3)2 Calcium nitrate 
CaCl2 Calcium chloride 
CARB Community-acquired bacterial pneumonia 
cDNA Complementary DNA 
CDS Coding sequence 
CHO Chinese hamster ovary 
CoCl2 Cobalt(II) chloride 
Cq Cycle of quantification value 
CRISPR/Cas9 Clustered regularly interspaced short palindromic repeats/ Caspase 9 
Ct Threshold cycle 
CTAB Cetyl trimethylammonium bromide 
CuSO4 Copper(II) sulfate 
cyc Terpene cyclase gene 
dH2O Deionised water 
dig-lig Digestion-ligation 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
dpi Days post infection 
EDTA Ethylenediaminetetraacetic acid 
ELSD Evaporate light scattering detector 
ER Endoplasmic reticulum 




FDA Food and Drug Administration 
FeSO4 Iron(II) sulfate 
FF Forward primer 
g Gravitational force 
G418 Geneticin® 
GCMS Gas chromatography-Mass spectrometry 
GFP Green fluorescent protein 
ggpps Geranylgeranyl pyrophosphate synthase gene 
GGS Geranylgeranyl pyrophosphate synthase 
GOI Gene of interest 
GT Gene targeting 
H2O Water 
H3BO3 Boric acid 
HCl Hydrochloric acid 
HPLC-MS High-pressure liquid chromatography-Mass spectrometry 
HSP Heat-shock protein 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IV Intravenous  
K2HPO4 Dipotassium phosphate 
kb Kilo bases 
KBr Potassium bromide 
KH2PO4 Monopotassium phosphate 
KI Potassium iodide 
KNO3 Potassium nitrate 
KOH Potassium hydroxide 
LacZ β-galactosidase 
LB Lysogeny Broth 
LB Left Border 
LiCl Lithium chloride 
mas Mannopine synthase 
MeOH Methanol 
MES 2-(N-morpholino)ethanesulfonic acid 
MgCl2 Magnesium chloride 
MgSO4 Magnesium sulfate 
MnCl2 Manganese(II) chloride 
MoClo Modular Cloning 
19 
 
mRNA Messenger RNA 
MRSA Methicillin-resistant Staphylococcus aureus 
N2 Nitrogen 
NaCl Sodium chloride 
NaFe(III) Sodium iron 
NaMoO4 Sodium molybdate 
NaOH Sodium hydroxide 
NCBI National center for Biotechnology Information 
NH4NO3 Ammonium nitrate 
NHK Nozaki–Hiyama–Kishi cyclization 
nos Nopaline synthase 
nptII Neomycin phosphotransferase II gene 
NTC Non-template control 
OD600 Optical density at a wavelength of 600nm 
osc Oxidosqualene cyclase 
P/Pro Promoter 
P450 Cytochrome P450 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
pH Potential of hydrogen 
PIPES Piperazine-N,N’-bis(2-ethanesulfonic acid) 
PKS Polyketide synthase 
pri-miRNA Primary micro-RNA 
PVP-40 Polyvinylpyrrolidone 
R/FR Red/ Far red light 
RB Right Border 
REU Relative expression unit 
RNA Ribonucleic acid 
rpm Revolutions per minute 
RR Reverse primer 
rRNA Ribosomal RNA 
Rt Retention time 
RT-qPCR Quantitative reverse transcription polymerase chain reaction 
sdr Short-chain dehydrogenase/reductase 
SDS Sodium dodecyl sulfate 
SnCl2 Tin(II) chloride 
SP Signal peptide 
20 
 
T Terminator  
TALEN Transcription activator-like effector nuclease 
T-DNA Transfer DNA 
TES Trace elements solution 
TU Transcription unit 
UTR Untranslated region 
UV Ultraviolet 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
YM Yeast Malt 






















Chapter 1: Introduction 
 
1.1 From traditional medicine to drug discovery 
Natural products have likely been used as medicinal agents since the origins of 
mankind, coming from a variety of sources, including plants, microbes and fungi. 
Ancient written records date back to 2,600BC in Mesopotamia, whilst Egyptian 
medicine has even earlier reports, from 2,900BC, with the Ebers Papyrus (Borchardt, 
2002; Newman & Cragg, 2010). Records from the Chinese Materia Medica 
demonstrate 52 prescriptions, documented from 1,100BC (Chang & But , 1986), 
while Ayuverda, the Hindu system of alternative medicine, dates back to 1,000BC 
(Kapoor, 2001).  
In ancient Greece, the philosopher and natural scientist, Theophrastus (100BC), 
reported the use of medicinal herbs in his book Historia Plantarium, while Galen 
(200AC), who practiced pharmacy and medicine in Rome, published prescriptions 
and formulas made of multiple ingredients (‘’galenicals’’). During the eighth century, 
Arabs created the first private drug stores and were the ones that preserved and 
expanded the existing Greco-Roman, Chinese and Indian records (Newman & Cragg, 
2010). 
 
1.2 Bioactive natural products from fungi 
Filamentous fungi are a source of bioactive natural products, which can have 
further applications in industry, agriculture or human medicine (Figure 1.1). 
Approaches where the native host is manipulated in order to increase the yields of 
these metabolites might be challenging, due to low efficiency genetic engineering or 
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highly demanding culture conditions (Alberti et al., 2017). For this reason, most 
approaches for heterologous expression of natural products are focused on 
Escherichia coli and the yeast Saccharomyces cerevisiae. Although E. coli is the most 
characterized prokaryotic model for protein expression and purification, and has been 
used for partial or sequential recreation of biosynthetic pathways, expression of large 
proteins such as polyketide synthases (PKSs) has been mostly unsuccessful. Amongst 
the limitations of this bacterial host is the inability to promote post-translational 
modifications that are required for functionality of some enzymes, and the fact that it 
has a different codon usage than eukaryotic fungi might compel codon optimisation 
for expression. Similarly, the most commonly researched group of natural products is 
antibiotics and antibiotic production in bacterial hosts can lead to toxicity or growth 
complications. S. cerevisiae is sometimes used for purification and catalytic 
characterisation of enzymes, by incubation of the substrate and the enzyme in vitro. 
This unicellular ascomycete fungus is widely used due to its rapid growth, the 
amenability for transformation and the promotion of most typical eukaryotic post-
translational modifications (Alberti et al., 2017; Da Silva & Srikrishnan, 2012; 
Sørensen & Mortensen, 2005). 
The fungal-derived β-lactam antibiotics, such as penicillins (1) and 
cephalosporins (2), contribute to over 40% of antibiotics in the human and veterinary 
drug market (Gidijala et al., 2010). Furthermore, fungal-derived fungicides as 
griseofulvin (3) and echinocandin (4) are used mainly for dermatophyte infections and 
candidiasis, respectively (Denning, 2002; Finkelstein et al., 1996). Strobilurins (12) 
are antifungal polyketides that paved the way for the production of synthetic 
derivatives, such as the β-methoxyacrylate class, used in crop protection. This class of 
fungicide gained a considerable 25% of the agricultural fungicide market (Nofiani et 
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al., 2018). Statins compromise another group of fungal natural products used in 
medicine, in order to lower cholesterol levels, including lovastatin (5) and mevastatin 
(6) (Manzoni & Rollini, 2002). Cyclosporin (7), originated from the fungus 
Tolypocladium inflatum, is an immunosuppressive agent for use in clinical organ 
transplantation (Cohen et al., 1984; Kahan, 1985). Another immunosuppressive agent, 
which also has anti-atherogenic properties and it is used as a treatment for multiple 
sclerosis, is the natural product myriocin (8) (Hojjati et al., 2005; Strader et al., 2011). 
Mycotoxins are a group of fungal secondary metabolites which contaminate food 
supplies and may cause mycotoxicosis in human and animals (Liew & Mohd-
Redzwan, 2018). Among mycotoxins, aflatoxins (9), derive from polyketides and are 
produced by Aspergillus flavus, A. parasiticus, and A. nomius (Kumaret al., 2017), 
ochratoxins (10) are produced by both Aspergillus and Penicillium species (Reddy & 
Bhoola, 2010), and trichothecenes (11) are found in genera including Fusarium, 
Myrothecium, Spicellum, Stachybotrys, Cephalosporium, Trichoderma and 
Trichothecium (McCormick et al., 2011). 
A group of natural products produced by bacteria, fungi and plants is tropolones 
(13), which consist of a core structure that is still rare among other natural products, 
including key steps of ring expansion (Cox & Al-Fahad, 2013). Cladosporin (14) is a 
nanomolar inhibitor of growth in both blood- and liver-stage of Plasmodium 





1.2.1 Using filamentous fungi as heterologous platforms 
When it comes to expression of complete biosynthetic pathways for secondary 
metabolites, filamentous fungi are preferred, since they can grow quickly using 
simple and inexpensive growth conditions and for this reason a lot of work is focused 
on cultivation and genetic engineering advancements (Nevalainen et al., 2005). In 
addition, fungal genes have relatively long exons and short introns compared to those 
of higher eukaryotes (Kupfer et al., 2004), and are generally compatible in translation 
folding and post-translational modifications. Moreover, their already active secondary 
metabolite machinery increases the availability of common precursors (Kjærbølling et 
al., 2019).  
 
Figure 1.1 Diversity of fungal bioactive natural products (adapted from Alberti et al., 2017).  
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Aspergillus species are the main platforms used for heterologous studies of 
gene clusters from different species. Nielsen and co-workers (2013), managed to 
incorporate the 13-genegeodin (15) cluster from A. terreus into A. nidulans, based on 
a successive gene targeting approach, geodin seems to act as a glucose uptake 
stimulator in rat adipocytes (Sato et al., 2005) and as an antifungal agent (Hargreaves 
et al., 2002). In the category of cholesterol-lowering agents, pravastatin (16), was 
successfully produced by McLean and co-workers, using P. chrysogenum, with the 
additional expression of a cytochrome P450 from Amycolatopsis orientalis to catalyze 
the conversion of compactin to pravastatin (McLean et al., 2015). Heneghan et al. 
managed to re-build the whole biosynthetic pathway of tenellin (17) derived from the 
insect pathogenic fungus, Beauveria bassiana, into Aspergillus oryzae and obtain the 
metabolite at a fivefold concentration (Heneghan et al., 2010). Apart from 
heterologous expression of the whole biosynthetic pathway, Fisch et al. proposed the 
reprogramming of polyketide synthases by rational domain swaps for the expression 
of tenellin (17) and desmethylbassianin (18) (Fisch et al., 2011). Ferrirhodin (19) acts 
as a siderophore related to iron acquisition and the characterisation of a nonribosomal 
peptide synthetase gene was accomplished by heterologous expression of the gene 
from F. sacchari to A. oryzae (Munawar et al., 2013).  
The first attempt at producing terpenoids into fungal hosts by transferring the 
whole biosynthetic pathway, was achieved by Fujii et al., where they followed a 
sequential transformation approach to express the four genes of the antibiotic 
aphidicolin (20) cluster into A. oryzae (Fujii et al., 2011). Paxilline (21) is a fungal 
indole-alkaloid tremorgenic known for its anti-MRSA properties and its biosynthetic 
pathway was reconstructed step-by-step from P. paxillin to A. oryzae, allowing the 
authors to elucidate the substrates of each enzyme (Tagami et al., 2013). Similarly to 
paxilline, aflatrem (22) was successfully produced after two rounds of A. oryzae 
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transformation, enabling the reconstruction of the 7-gene pathway from A. flavus 
(Tagami et al., 2014). The first effective heterologous reconstruction of a secondary 
metabolism biosynthetic pathway from a basidiomycete to an ascomycete fungus was 
accomplished by Bailey et al., where a 7-gene cluster, encoding for the antibiotic 
pleuromutilin (23), was stepwise introduced from Clitopilus passeckerianus to A. 
oryzae, leading to a significant twentyfold increase in production (Bailey et al., 2016). 
Another example of total biosynthesis comes from the work of Liu et al., where a 
basidiomycete metabolite erinacine Q (24), a diterpene with neuroprotective 
properties derived from Hericium erinaceus, was produced in A. oryzae by applying 
CRISPR/Cas9-mediated homologous recombination (Liu et al., 2019). 
 
1.2.2 From gene clusters to biosynthetic pathways 
Secondary metabolites are usually encoded by genes that are physically grouped 
in the genome, called biosynthetic gene clusters (BGCs) and can be found in bacteria, 
fungi and plants (Osbourn, 2010; Tran et al., 2019). A BGC contains all the genes 
encoding the functional enzymes of the pathway, tailoring enzymes and regulatory 
elements, such as transcription factors (Figure 1.2). In some cases, it might also 
contain genes responsible for exportation and transportation of the produced 
molecules or resistance genes to protect the producer from the potentially harmful 
metabolites (Medema & Fischbach, 2015; Tran et al., 2019). Physical clustering 
provides the opportunity for coordinated regulation of gene expression as all the genes 
would be in a similar chromatin context, allowing the coordinated activation of 
cryptic clusters using chromatin modifying agents (Hurst et al., 2004; Sproul et al., 
2005). Another reason for co-localisation of these genes may be linked to the selective 
advantage of coinheritance of the entire pathway and of favourable combinations of 
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alleles (Nei, 1967; Osbourn, 2010). Transcriptional regulation of fungal BCGs is 
complex and can be affected by various environmental stimuli such as carbon and 
nitrogen concentrations, temperature, light, pH, reactive oxygen species, amino acids 
and stimuli from other organisms. Regulation can occur at a global level, where the 
regulatory proteins are globally acting transcription factors regulating a plethora of 
genes that do not participate in secondary metabolism (e.g. LaeA, PacC, Cre1; Figure 
1.2) and a pathway-specific level, where those specific transcription factors are also 
encoded by genes involved in the respective cluster (Brakhage, 2013). 
Clustering of genes that produce secondary metabolites facilitates their 
identification. Most secondary metabolites fall into a limited group of chemical 
classes (terpenes, polyketides or non-ribosomal peptides) and the core synthases for 
these are readily identifiable by homology searches such as BLAST. The adjacent 
genomic regions can then be analysed for likely tailoring genes and other elements 
needed for secondary metabolite production. Analysis of the rapidly expanding 
number of fungal genomic sequences led to the observation that the BGCs 
outnumbered the known natural products, therefore indicating a bigger variety of 
these products within the same organism and that therefore most BGCs are silent or 
not active enough during laboratory conditions to lead to a detectable product  
(Kjærbølling et al., 2019). In order to associate a secondary metabolite with a BGC, it 
is important to take into consideration whether the native strain is amenable to 
transformation and/or it can grow quickly in laboratory conditions. The next question 
is whether this BGC is silent or active within the strain, so as to follow external 
stimuli or genetic engineering to activate it, or gene deletion strategies to eliminate its 
expression. Heterologous expression is still considered the most preferred option 
when elucidating and characterising biosynthetic genes and pathway precursors. 
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Various bioinformatic tools facilitate the assembly and identification of BGCs 
following one of the strategies: (1) Homology search – having a known similar 
compound in two organisms, where the biosynthetic cluster has been identified in 
either of those (2) Retro biosynthesis – having a known compound but no cluster 
identification, predicting the enzymes activities and therefore any putative clusters 
that encode these enzymes and (3) Comparative genomics – comparing genomes of a 
set of organisms that may or may not produce the compound under study and discover 
gene clusters that are homologous in the producing species and filter them based on 
no homologs in the non-producing (Kjærbølling et al., 2019; Lazarus et al., 2014; 
Schmidt-Dannert, 2015). 
 
Figure 1.2 A generalised biosynthetic gene cluster, consisting of backbone synthase genes, tailoring 
genes, regulatory elements and transporters(Lazarus et al., 2014). 
 




1.3.1 Isolation, origin and mechanism of action 
Pleuromutilin is a tricyclic diterpene, produced by the basidiomycetes 
Pleurotusmutilus (Clitopilusscyphoides) and Pleurotus passeckerianus (Clitopilus 
passeckerianus), and its skeleton can be used for semi-synthesis of derivatives (Figure 
1.3) (Bailey et al., 2016). The basidiomycetes belong to the subkingdom Dikarya and 
are an often underexploited phylum of fungi that can deliver various medicinal 
benefits, including not only antibacterial, but also immunomodulatory, anticancer, 
antiviral, cardio and hepatoprotective properties (de Mattos-Shipley et al., 2016). In 
most fungal natural products, the yields in the native host are very low, and 
fermentation or isolation of these compounds can be demanding. This also applies to 
C. passeckerianus, where traditional strain improvement, like random mutagenesis is 
achievable due to their dikaryotic nature (Bailey et al., 2016). 
 
Figure 1.3 (A) A mature Clitopilus passeckerianus fruiting body. (B) Chemical structure of 
pleuromutilin (de Mattos-Shipley et al., 2017; Newman & Cragg, 2010). 
 
Pleuromutilin and its producing strains were first isolated and reported by 
Kavanagh et al. in the early 1950s (Kavanagh et al., 1951; Kavanagh et al., 1952), 
where it displayed a potent activity against Gram-positive bacteria, particularly 
Staphylococcus aureus. The unique mechanism of action involves binding to the 
highly conserved peptidyl transferase centre of the bacterial ribosome. Hence, 
resistance to pleuromutilin is slow to be established, and it demonstrates minimal 
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potential for cross-resistance with existing antibiotics. The glycolic acid residue 
interacts via hydrogen bonding with the P-site of the protein translation centre (Figure 
1.4) (Davidovich et al., 2007; Paukner & Riedl, 2017). The primary binding 
interactions of pleuromutilin with the ribosome originates from its tricyclic centre 
(Murphy et al., 2017). The majority of semi-synthetic efforts have focused on 
modification of the C14 side chain (Fazakerley & Procter, 2014; Paukner & Riedl, 
2017), indeed more than 3,000 C14 derivatives have been produced. Until now, the 
three mechanisms of resistance to pleuromutilin consist of mutations in 23S rRNA 
and rplC genes encoding the ribosomal protein L3, methylation of the nucleotide 
A2503 which blocks pleuromutilin binding, and drug efflux by ATP-binding cassette 
(ABC) transporters (Goethe et al., 2018). 
 
Figure 1.4 (A) Schematic of protein translation. (B) Partial structure of tiamulin and (C) retapamulin 
bound to the 50S ribosomal subunit of D. radiodurans (Davidovich et al., 2007; Goethe et al., 2018; 
Schlünzen et al., 2004). 
1.3.2 Early studies of structure and biosynthesis of pleuromutilin 
Structural studies were first published in 1952, describing the molecular structure 
of pleuromutilin (C22H34O5) and correctly accrediting three of the five oxygen atoms 
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as two non-phenolic hydroxyl groups and one hindered carbonyl group. The 
remaining two oxygen atoms were experimentally assigned to a lactone ring (Anchel, 
1952); this was later corrected, and shown to be the ester functionality at C14. Birch 
and Arigoni eventually generated the full and correct structure of pleuromutilin, 
giving also a proposed biosynthetic pathway, thus identifying pleuromutilin as the 
glycolic ester of the diterpene mutilin (Birch et al., 1966; Arigoni, 1968). 
 
1.3.3 Chemical Synthesis of pleuromutilins 
The first attempt of pleuromutilin chemical synthesis reported in 1980 by 
Kahn, where he focused on access to the synthetic core, examining the coupling of a 
vinyl anion fragment to a spirocyclobutanone derivative which would lead to the 
skeleton of pleuromutilin via the oxy-Cope rearrangement (Kahn, 1980). Two years 
later, Gibbons reported the total synthesis of pleuromutilin through a 12-step 
procedure, initiating with a sequential Michael reaction. After acquiring the tricyclic 
core, he started modifying it and completed the synthesis of pleuromutilin in a further 
17 steps (Gibbons, 1982). In 2013, Fazakerley et al. reported the first enantiospecific 
total synthesis of pleuromutilin (Fazakerley et al., 2013). An 18-step synthesis of 
pleuromutilin was revealed by Farney et al. that enabled the preparation of mutilin 
derived antibiotics (Farney et al., 2018). In contrary to semisynthesis, de novo 
synthesis of pleuromutilins was reported by Liu et al., where ring-closing metathesis 
led to a modified pleuromutilin core via Nozaki–Hiyama–Kishi (NHK) cyclization to 
create C5, C6, C10-des-methyl pleuromutilin derivatives (Liu et al., 2011). These 
chemical syntheses were all constrained by being multi-step and typically low-




1.3.4 Recent identification of pleuromutilin gene cluster 
In 2016, Bailey et al. attempted to identify the genes involved in the 
biosynthesis of pleuromutilin (Bailey et al., 2016). Fungal diterpene pathways 
typically include a pathway-specific geranylgeranyl pyrophosphate synthetase 
(GGS), so their study looked to isolate such genes by PCR and identify which was 
the best candidate for pleuromutilin synthesis. Northern blots performed on RNA 
extracted from the fungus grown under production and repression conditions 
identified a GGS whose expression was consistent with pleuromutilin production 
and sequencing the surrounding genomic region identified more candidate genes as 
being part of the cluster. After testing gene expression levels, a cluster of seven 
genes appeared to be tightly co-regulated and were attributed to the gene cluster 
responsible for pleuromutilin biosynthesis. The cluster is composed of 3 cytochrome 
P450 genes (p450-1,-2,-3), an acetyltransferase (atf) and terpene cyclase (cyc) gene, 
a geranylgeranyl pyrophosphate synthase (ggpps) and a short-chain 
dehydrogenase/reductase (sdr) gene (Figure 1.5 A). The link between those genes 
and pleuromutilin production was proved by a gene silencing approach, where 
silence of ggpps or cyc led to an 87% reduction of pleuromutilin titre and a direct 
decline in bacterial clearing zones. It is also noteworthy that gene silencing of an 
individual gene from the cluster generated downregulation of all other cluster genes.  
One year later, Yamane et al., (2017) characterised all of the biosynthetic 
intermediates of pleuromutilin pathway and through draft-genome sequencing of the 
closely related strain C. pseudo-pinsitus, they reported an identical gene 
organisation to that of Bailey et al., 2016. In summary, in order to propose the 
detailed pathway of pleuromutilin and characterize the function of all enzymes of the 
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pathway they conducted in vitro enzymatic reactions using a diterpene synthase, and 
in vivo synthesis by heterologous expression in A. oryzae (Figure 1.5 B).  
 
Figure 1.5 (A) Pleuromutilin BGC: ggs, GGPP synthase gene; cyc, terpene synthase gene; p450-1,-
2,-3, cytochrome P450s genes; sdr, short-chain dehydrogenase gene; atf, acetyltransferase gene (Bailey 
et al., 2016). (B) Proposed biosynthetic pathway of pleuromutilin (1) (Yamane et al., 2017); GGPP, 
geranylgeranyl diphosphate; ggs/ ple4, GGPP synthase; cyc/ ple3, terpene synthase; p450-1,2,3/ ple1, 
ple5, and ple6, cytochrome P450s; sdr/ ple7, short-chain dehydrogenase/ reductase; atf/ ple2, 
acetyltransferase. 
However, the proof-of-principle for gene function was accomplished by 
conducting stepwise heterologous expression in A. oryzae, which resulted to detailed 
structural elucidation of the pleuromutilin pathway intermediates (Figure 1.6) 




Figure 1.6 Proposed biosynthetic pathway of pleuromutilin (Alberti, et al., 2017); GGPP, 
geranylgeranyl diphosphate; ggs, GGPP synthase; cyc, terpene synthase; p450-1, 2, 3, cytochrome 
P450s; sdr, short-chain dehydrogenase/reductase; atf, acetyltransferase. 
 
1.3.5 Enhancement of pleuromutilin production  
 
1.3.5.1 Attempted overexpression in the native host C. passeckerianus 
Experimental overexpression of the putative gene cluster was carried out in the 
native host C. passeckerianus using either native promoters or the constitutive 
promoter gpdII from Agaricus bisporus. However, in both cases not only there was 
no significant increase in pleuromutilin production but also often reduced or no 
bacterial clearing zones were observed, thus proving a complete loss of antibacterial 
activity, likely indicating a type of endogenous sense-suppression in C. 
passeckerianus (Bailey et al., 2016). As a final attempt, the whole putative gene 
cluster along with the neighboring genes was expressed in the native host, thus 
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revealing that only 16 out of 119 transformants showed a 20-40% increase in 
clearing zone diameter.  
1.3.5.2 Successful heterologous expression in Aspergillus oryzae 
Heterologous expression of the putative pleuromutilin gene cluster from a 
basidiomycete (C. passeckerianus) to an ascomycete (A. oryzae) and successful de 
novo production of pleuromutilin were first accomplished by Bailey and co-workers 
(Bailey et al., 2016).  In this study, every transformant that successfully expressed 
all seven genes of the cluster resulted in expansion of the clearing zone, thus 
confirming the production and secretion of an antibacterial compound. HPLC-MS 
analyses demonstrated a considerable increase of 2,016% in pleuromutilin 
production, but the yield was still very limited for pharmaceutical purposes (Alberti et 
al., 2017). According to the study, this poor yield might due to the use of the enolase 
promoter used for the genes cyclase, p450-1 and short-chain dehydrogenase.  
1.3.6 Pleuromutilin derivatives and clinical potential 
All of the pleuromutilin derivatives used in veterinary and human medicine 
have modifications in the C14 side chain, where some of the analogues consist of 
carbamate or acyl carbamate linkers (Figure 1.7). It is worth mentioning that only the 
sulfanylacetyl derivatives were successful in proceeding to clinical trials (Goethe et 
al., 2018). Tiamulin and valnemulin were the first pleuromutilin derivatives used for 
veterinary purposes, being active against a broad spectrum of Gram-positive bacteria 
(Poulsen et al., 2001). Moreover, the approval of retapamulin in 2007 for the 
treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections (Jones et 
al., 2006) and the development of lefamulin for the treatment of community-acquired 
bacterial pneumonia (CARB), which has been recently approved by the Food and 
Drug Administration (FDA) for human oral and intravenous use, pave the way for 
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more studies in the field (File et al., 2019). The lefamulin C14 side chain contains a 
thioether bond that increases its solubility and metabolic stability, which promotes the 
oral and intravenous use. This side chain also eliminates resistance development by 
increasing the number of hydrogen bonds to the target (Veve, 2018). 
 
Figure 1.7 Clinical and pre-clinical pleuromutilins (1): (A) Veterinary antibiotics tiamulin (2) and 
valnemulin (3), (B) Retapamulin (4): human topical, short-term treatment for skin and soft tissue 
infections, (C) Lefamulin (5): human systemic use for various clinical conditions including community 
acquired bacterial pneumonia (CARB), pre-clinical agents azamulin (59), BC-3205 (60) and BC-7013 







1.4 Plants as biosynthetic machinery for secondary metabolites 
 When it comes to heterologous hosts, plants have several benefits that make 
them a preferable expression platform. In order to grow, they simply require water, 
carbon dioxide, inorganic nutrients and light rather than expensive culture media. 
They will grow on a field-scale with conventional farming equipment rather than 
needing specialist facilities such as fermentors so are ideal for use in developing 
countries as well as those with more developed biotech industries. The challenges in 
finding the ideal host for heterologous production are numerous, including fine-tuning 
of expression levels, delivering cofactors, precursors and obtaining the desired post-
translational modifications (Smanski et al., 2017). 
 
1.4.1 A moss-based expression platform 
Mosses belong to the bryophyte sister lineage of vascular plants, sharing many 
gene families with Arabidopsis but with less redundancy (Ishizaki, 2017). The 
dominant phase of moss lifecycle is haploid (gametophytic), like in algae, while the 
dominant phase in all seed plants is at least diploid (sporophytic) (Figure 1.8; Reski et 
al., 2015). The moss Physcomitrella patens is a well-established model organism, 
with a fully sequenced genome and efficient homologous recombination, making it an 
attractive biotechnological candidate. Due to the dominant haploid lifecycle, 
backcrossing for establishment of homozygous transgenic lines is not necessary. As a 
photosynthetic organism, its subcellular compartments can create tailored 
microenvironments. It is able to grow in large-scale liquid culture, while ensuring 
homogeneity and reproducibility of production. The simple terpenoid profile means it 
has fairly a clean metabolic background, although P. patens produces large quantities 
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of endogenous diterpenes (Khairul Ikram et al., 2017; King et al., 2016). For this 
reason, Physcomitrella has been used as a production host for commercial 
diterpenoids, such as taxadiene and sesquiterpenoids like the anti-malarial drug 
artemisinin. In addition to simple metabolites, mosses display a diverse engineering 
platform with applications in pharmaceutical protein production, biomimetics for 
regenerative medicine and indeed in modifying extreme environments for halting 
greenhouse gas emissions (Decker & Reski, 2020). 
 
Figure 1.8 Physcomitrella patens (A) life cycle, where development starts from the haploid spore, 
which forms protonema, a tip growing filamentous tissue. During the juvenile-to-adult transition of the 
moss gametophyte, the protonema forms buds which contain a three-faced apical meristematic cell 
(Harrison et al. 2009) able to generate the leafy gametophore. Within several weeks of inducing 
conditions (15 °C short day), male and female sexual organs are produced and an example of (B) a 
stirred tank photobioreactor for small-scale production (Decker & Reski, 2020; Harrison et al., 2009; 
Müller et al., 2016). 
 
1.4.1.1 Methods and approaches in moss genetic engineering  
The high rate of accurate gene targeting (GT) via homologous recombination 
is a clear benefit for engineering of moss compared to similar approaches in seed 
plants (Reski et al., 2015). Furthermore, base-specific genome modifications are 
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relatively easy to obtain and production of fusion proteins is possible (Mosquna et al., 
2009; Mueller et al., 2014), along with down-regulation of native gene expression via 
synthetic microRNAs (Khraiwesh et al., 2008; Reski et al., 2018). In addition, in 
planta assembly of gene constructs was accomplished in the same moss (King et al., 
2016), an approach initially established in Saccharomyces cerevisiae (Gibson, 2009). 
An additional benefit is that the rescue of episomally replicating DNA is also possible 
in P. patens (Murén et al., 2009), making it easy to manipulate and exploit as a 
synthetic biology platform. These results showed the possibility of integrating 
megabase extended gene constructs into the moss genome, an important tool of 
synthetic biology so far only known from yeast. Advancement of protocols for culture 
media, protoplast isolation and regeneration, and for PEG-mediated transformation, 
enables the incorporation of multiple different genes in a single experiment (Hohe et 
al., 2004; Hohe & Reski, 2002; Reski et al., 2018). 
Development of auxotrophic moss mutants led the way for new selection 
markers (Ulfstedt et al., 2017) and these facilitate multiple rounds of transformation. 
Transgene expression methods in moss use various promoter elements, such as 
endogenous, bacterial and seed plant promoters (Holtorf et al., 2002; Jost et al., 2005; 
Reutter et al., 1998). The combination of suitable promoters enables regulated gene 
expression control, (Horstmann et al., 2004), induced either by temperature, 
chemicals or red light (Kubo et al., 2013; K. Müller et al., 2014; Saidi et al., 2005). 
Elements important for transcription, translation or secretion used in P. patens 
were first established and optimised for recombinant protein production in CHO cells 
(Gitzinger et al., 2009). Recent studies reveal that artificial promoters can be an 
excellent option for the expression of multiple genes (Peramuna et al., 2018). 
Synthetic promoters have relatively short sizes but possess sufficient activity. 
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Moreover, recombinant proteins can directly be secreted through the ER to the 
medium where P. patens grows by utilizing endogenous signal sequences (Schaaf et 
al., 2005). As an alternative, there is a case where the product is integrated into the 
cell membrane, thus giving to this moss extracellular catalytic or binding properties 
(Morath et al., 2014). 
Although plants reveal a high consistency of N-glycosylation throughout 
tissues and across species, the basic structure of N-glycosylation is conserved between 
humans and plants (Bosch et al., 2013). Where glycosylation was inappropriate, genes 
that encoded plant-derived glycosyltransferases have been identified and eliminated 
from the moss (Koprivova et al., 2004; Parsons et al., 2012). A different approach 
involved a moss mutant with the ultimate aim to ‘‘humanise’’ glycosylation in moss 
by expressing human beta-1,4-galactosyltransferase (Huether et al., 2005). 
 
1.4.2 Liverworts in biotechnology 
Liverworts, along with mosses and hornworts, belong to the non-vascular 
group of bryophytes. The dominant form of their development is a gametophyte 
thallus that is haploid and dioecious, while they can propagate both sexually and 
asexually through vegetative propagules, called gemmae (Figure 1.9) (Kubota et al., 
2013). The majority of secondary metabolites found in liverworts are lipophilic mono-
, sesqui-, diterpenoids, aromatic compounds and acetogenins, however nitrogen- and 
sulfur-containing compounds are very rare. The most characteristic feature of their 
chemical diversity is that most of sesqui- and diterpenoids are enantiomers of those 
found in higher plants (Adam & Becker, 1993; Asakawa & Ludwiczuk, 2013; 
Asakawa et al., 2013). Interestingly, Marchantin A, the first characterized cyclic 
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bis(bibenzyls) from Marchantia polymorpha has pharmacological potential, showing 
anticancer, antifungal, antimicrobial, antioxidant and muscle relaxing activity (Gaweł-
Bęben et al., 2019; Jantwal et al., 2019; Takahashi & Asakawa, 2017). The liverwort 
M. polymorpha has been extensively studied, mainly to address the evolution of land 
plants and gene function. However, it was also used as the first plant platform for 
prostaglandin production, since it accumulates the substrate arachidonic acid, by 
introducing a cyclooxygenase gene into the M. polymorpha genome from the red alga, 
Gracilaria vermiculophylla (Takemura et al., 2013).  
 
Figure 1.9 Life cycle of Marchantia polymorpha. A haploid spore germinates and develops into a 
thallus. A group of cells developing from a spore is called a sporeling. Under white light a sporeling 
grows into a sphere-like cell mass (a. germination/ high R light). A thallus is a multilayered 
gametophyte body with dorsoventrality that has a growing point at the apical notch of each lobe, which 
undergoes periodical bifurcations. In the vegetative growth phase, dozens of clonal progeny, gemmae, 
42 
 
are produced in gemma-cups, which are formed repeatedly on the dorsal side of a thallus. After 
dispersion and water uptake, each gemma develops into an individual thallus (b. vegetative 
propagation/ gemma to gemmaling). M. polymorpha transits from vegetative to reproductive growth 
under a long-day condition supplemented with far-red light (FR), and develops gametangiophores on 
the thallus (c. transition to reproductive growth phase/ FR light). The male gametangiophore is called 
an antheridiophore and contains antheridia, and the female gametangiophore is called an 
archegoniophore and has archegonia. Sperm released into water swim up the neck of the archegonium 
and fertilize the eggs. The zygote undergoes mitotic divisions, and develops into a multicellular diploid 
sporophyte. Nutrients are supplied to the developing sporophyte from the surrounding gametophyte 
tissues. Meiosis occurs inside the sporangium, and hundreds of thousands of haploid spores are 
produced per sporangium (Ishizaki et al., 2016; adapted from Schmid et al., 2018). 
 
1.4.2.1 Tools and techniques for Marchantia research 
Given the haploid nature of M. polymorpha, genetically homogeneous lines 
can be established easily. Most characterized gene regulatory elements are common 
between Marchantia and higher plants like angiosperms, while gene families are 
sparsely populated (Bowman et al., 2017). Whole-genome analysis proves that genes 
responsible for growth and development are conserved but with low redundancy in M. 
polymorpha (Ishizaki et al., 2016).  
M. polymorpha can reproduce both sexually and asexually and for this reason 
various transformation techniques have been established. Physical DNA delivery via 
particle bombardment to the nuclear genome was achieved using 2-week old thalli 
grown from gemmae (Takenaka et al., 2000). Agrobacterium-mediated genetic 
transformation, which is now the most common technique, can generate transgenic 
plants using sporelings, mature thalli, intact male and female gemmae or regenerating 
thalli derived from either sex, giving isogenic lines in four to six weeks (Kubota et al., 
2013; Tsuboyama & Kodama, 2018). Furthermore, plastid transformation is available 
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for suspension-cultured cells and sporelings. It is worth mentioning that despite 
multiple plastid genome copies, homoplasmic transformants of thalli can be obtained 
immediately after primary selection from sporelings and after 12-16 weeks of 
repeated subculture from suspension-cultured cells (Chiyoda et al., 2007; Chiyoda et 
al., 2014).  
Although homologous recombination is highly efficient in P. patens, gene 
targeting in this manner is difficult in M. polymorpha. While using haploid tissue is 
theoretically impossible to produce knockout plants for essential genes, conditional 
gene knockout strategies have been established. Nishihama et al., (2015) created a 
heat- and dexamethasone-controllable gene expression/deletion system by using a 
promoter of a heat-shock protein (HSP) gene and the Cre/lox P site-specific 
recombination system.  Alternatively, artificial microRNA-mediated knockdown was 
successfully established, using both endogenous and heterologous primary microRNA 
(pri-miR) hairpin backbones (Flores-Sandoval et al., 2015). Two different 
Transcription Activator-Like Effector Nuclease (TALEN) techniques were conducted, 
using custom and self-assembled TALEN constructs, with both approaches being 
successful in yielding high efficiencies of over 20% (Kopischke et al., 2017). 
Moreover, Clustered Regularly Interspaced Short Palindromic 
Repeat/CRISPR‐associated protein 9 (CRISPR‐Cas9) technology has been used in M. 
polymorpha using Arabidopsis-codon-optimized Cas9 (Sugano et al., 2018).   
Recently, Sauret-Güeto et al., (2020) developed the type II OpenPlant toolkit 
which includes vectors for nuclear and chloroplasts transformation, and for CRISPR 
genome editing, along with a collection of standardized DNA basic parts for 
expression in Marchantia, including antibiotic resistance genes, signal peptides, 
fluorescent proteins for multispectral imaging and promoters for gene expression 
44 
 
(Figure 1.10). Also, they include techniques for high-throughput microscopic imaging 
of multiple Marchantia lines, where gemmae are cultured in multiwell plates. 
 
Figure 1.10 Basic (Level 0) DNA parts in the OpenPlant toolkit. The OpenPlant kit contains: 
promoters with 5’ UTR (PROM5), promoters (PROM) and 5’ untranslated region (5UTR); coding 
sequences with start and stop codons (CDS), and for N-terminal (CTAG) and C-terminal (CDS12) 
protein fusions, and 3’ UTR with terminator (3TERM). The OpenPlant toolkit contains 50 basic parts, 
43 for nuclear transformation, 3 for CRISPR-Cas9 genome editing (in green), and 7 for chloroplast 








1.4.3 Nicotiana species for biopharmaceutical production 
The cultivated tobacco Nicotiana tabacum is the main source for nicotine, given 
that other plants containing nicotine and nicotine-like alkaloids appear to be toxic for 
human use (San Andrés Larrea et al., 2014). N. tabacum cells are the most frequent 
plant suspension cells used in biotechnology, grown in stirred tanks and bioreactors, 
since transformation methods and propagation are simple and reproducible (Wuest et 
al., 2011). Cell suspensions can be transformed with recombinant plasmids either by 
co-cultivation with A. tumefaciens or particle bombardment (Hellwig et al., 2004). 
Genetic transformation strategies like CRISPR/Cas9 and TALEN have been also 
successful (Gao et al., 2015; Y. Zhang et al., 2013). N. benthamiana is often used for 
transient expression, while N. tabacum is typically used for production of stable 
transgenic plants, a procedure that requires a longer period of development (Garabagi 
et al., 2012). Various valuable therapeutic and diagnostic proteins have been produced 
in Nicotiana plants, including secondary metabolites (Reed & Osbourn, 2018; Bo 
Wang et al., 2016), enzymes (Kytidou et al., 2017; Vardakou et al., 2012), viral 










1.5 Aims of this project 
This project aimed to evaluate the available expression platforms to allow 
complex multigene expression in various plants. As previously described, the plant 
hosts that were chosen for this project was Physcomitrella patens, Marchantia 
polymorpha and Nicotiana tabacum. Prior to transformation it was essential to assess 
the host plants for sensitivity and/or resistance to mutilins. P. patens and M. 
polymorpha were screened due to the stable transformation approach for these plants. 
Furthermore, in order to express the pleuromutilin pathway in these hosts the 
appropriate constructs were designed and built to be functional in the different plant 
chassis. After successful transformation of M. polymorpha and transient expression in 
















Chapter 2: Materials and Methods 
 
2.1 Laboratory supplies 
Chemical reagents were purchased from Sigma-Aldrich, Fisher, Honeywell, Acrȏs 
Organics, VWR, Formedium and Merck. Laboratory consumables and glassware were 
used from Fisher, VWR and Sarstedt, while primers used were supplied from 
Integrated DNA technologies. DNA ladder, enzymes and buffers derive from New 
England BioLabs and Thermo. All solutions and media were prepared in deionised 
water. All solutions, media and glassware were autoclaved at 121°C for 15 minutes 
unless otherwise stated. 
 
2.2 Species used in this project 
 
2.2.1 Bacterial Species, growth and maintenance 
The Escherichia coli strain used for plasmid transformation and propagation 
was TOP10. The Agrobacterium tumefaciens strain LBA4404 was used for stable or 
transient transformation methods for Marchantia polymorpha and Nicotiana tabacum, 
respectively. Solid and liquid media were autoclaved at 121°C for 15 minutes and 
allowed to cool to approximately 50°C before adding the appropriate antibiotics or 
selection reagents (Table 2.1). Agar-based media were poured into sterile 90mm Petri 
dishes, left to solidify under sterile laminar air flow and stored at 4°C until use. Plates 
and liquid cultures containing transformed cells were then stored at 4°C until 
screening and verification via DNA sequencing. 
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E. coli were grown overnight at 37°C on LB agar (LB Agar Lennox, Tryptone 
10g/l, Yeast Extract 5g/l, NaCl 5g/l, agar 15g/l). Liquid cultures were grown with 
additional agitation at 200rpm (LB Broth Lennox, Tryptone 10g/l, Yeast Extract 5g/l, 
NaCl 5g/l). All cultures were supplemented with appropriate antibiotics prepared as 
shown in Table 2.1. Aliquots of liquid cultures of the correct transformed clones were 
stored in 20% glycerol and kept at -80°C. 
A. tumefaciens strain LBA4404 cells were grown for 2-3 days at 28°C, with 
agitation at 200rpm for liquid cultures, on YM agar or YM broth (Mannitol 10g/l, 
Yeast Extract 0.4g/l, K2HPO4 0.5g/l, NaCl 0.1g/l, MgSO4 7H2O 0.2g/l, for plates: 
agar 15g/l), supplemented with appropriate antibiotics as shown in Table 2.1. Aliquots 
of liquid cultures of the correct transformed clones were stored in 20% glycerol and 
kept at -80°C. 
Table 2.1 Antibiotics used for E. coli and A. tumefaciens cells. 
Organism Antibiotic/Reagent Stock 
Concentration 
Dissolve in Working 
Concentration 
E. coli Ampicillin 100mg/ml H2O 100μg/ml 
 Carbenicillin* 50mg/ml H2O 100μg/ml 
 Kanamycin 50mg/ml H2O 50μg/ml 
 Spectinomycin 40mg/ml H2O 80μg/ml 
 X-gal 20mg/ml DMF 20μg/ml 
 IPTG 100mM H2O 100μM 
A. tumefaciens Ampicillin 100mg/ml H2O 100μg/ml 
 Carbenicillin 50mg/ml H2O 75μg/ml 
 Kanamycin 50mg/ml H2O 50μg/ml 
 Rifampicin 20mg/ml MeOH 20μg/ml 
 Spectinomycin 40mg/ml H2O 250μg/ml 
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 Streptomycin 100 mg/ml H2O 100 μg/ml 
 Acetosyringone 0.1M DMSO 20-100μM 
*carbenicillin can replace ampicillin, as it is more chemically stable 
2.2.2 Plant Species, growth and propagation 
The moss Physcomitrella patens WT04 line and the liverwort Marchantia 
polymorpha Tak-1 line (or Takaragaike-1 line, male line) were used for the 
establishment of stable transformants, while Nicotiana tabacum SR1 line was used for 
transient expression experiments. Both P. patens and M. polymorpha were given by 
Dr Jill Harrison and N. tabacum was provided approximately 4-week old by the Life 
Sciences Building greenhouse facility. Plant media were autoclaved at 121°C for 15 
minutes and allowed to cool to approximately 50°C before adding the appropriate 
antibiotics or supplements. Agar plates were poured into sterile square 
100x100x20mm (Sarstedt, Australia) or 25 compartments (Thermo Fisher Scientific, 
UK) Petri dishes, left to solidify under laminar flow hood and stored at 4°C until use. 
When using plates for propagation, antibiotic treatment assays, PEG-mediated 
transformation in P. patens or during selection, Petri dishes were sealed with 3M 
Micropore® surgical tape. P. patens grew on BCD-AT medium, and M. polymorpha 
on half-strength Gamborg’s B5 (Table 2.2), both in a 22°C growth chamber under 
continuous light and 40% Relative Humidity. P. patens can be propagated by 
subculturing any kind of tissue (e.g. protonemata, leaves) using forceps, while M. 






Table 2.2 Plant media for P. patens and M. polymorpha.  
Organism Media  
P.patens BCD-AT Stock solutions B, C, D, AT 10ml/l 
1x TES 1ml/l,  
1M CaCl2 1ml/l * 
Plant agar 8g/l 
 
Stock solutions*: 
B: MgSO4.7H2O 25g/l 
C: KH2PO4 12.5g/l pH 6.5 with KOH 
D: KNO3 101g/l, FeSO4.7H2O 1.25g/l 
0.5M AT: di-ammonium (+) tartrate 92g/l 
20x trace elements solution (TES): H3BO3 12.28g/l, 
MnCl2.4H2O 7.78g/l, AlK(SO4)2.12H2O 1.1g/l, 
CuSO4.5H2O 1.1g/l, CoCl2.6H2O 1.1g/l, ZnSO4.7H2O 
1.1g/l, KBr 0.56g/l, LiCl 0.56g/l, KI 0.56g/l, 
SnCl2.2H2O 0.56g/l 
 
M. polymorpha Half-strength Gamborg’s B5 
supplemented with 1% (w/v) 
sucrose 
Gamborg’s B5 Basal Salt Mixture (Sigma®)1.5g/l 
Sucrose 10g/l 
Plant agar 8g/l 
pH 5.8 with KOH 
*CaCl2 and all stock solutions were filter sterilised and added to the autoclaved plant agar after cooling 
to 50°C. 
 
2.3 Antibiotic treatment assays 
Both P. patens and M. polymorpha were grown using media described 
previously, and these were supplemented with dilution series of antibiotics that cover 
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a wide range of mechanisms of action, including pleuromutilin derivative, tiamulin, 
and mutilin. Denagard® (tiamulin hydrogen fumarate) was used as a semi-synthetic 
antibiotic belonging to the pleuromutilin group of antibiotics, while mutilin was 
organically synthesized by the PhD student Jonathan Davies from the School of 
Chemistry, University of Bristol. Plant media were supplemented with all of the 
antibiotics listed in Table 2.3 at concentrations of: 0μg/ml (untreated), 1μg/ml, 
5μg/ml, 10μg/ml, 50μg/ml, 100μg/ml, 200μg/ml, 250μg/ml and 500μg/ml. 
Table 2.3 Antibiotics used for toxicity tests for P. patens and M. polymorpha 
Mechanism of action Class Antibiotic Stock Concentration 




Aminopenicillins Ampicillin 100mg/ml in dH2O 
Protein synthesis 
inhibition – interaction 




50mg/ml in dH2O 
Protein synthesis 
inhibition – interaction 











20mg/ml in EtOH 
 
 









2.4 Construction of plasmids 
The plasmids were assembled using the MoCloPlantToolkit (Addgene Kit 
#1000000044) and the Golden Gate Plant Parts Kit (Addgene Kit #1000000047), 
which contain a collection of 95 empty standardized vectors and 95 standardized plant 
parts, respectively, facilitating the design of multigene constructs for plant 
transformation (Engler et al., 2014; Marillonnet & Werner, 2015; Weber et al., 2011; 
Werner et al., 2012). 
2.4.1 Modular Cloning (MoClo) using the Golden Gate® assembly 
Golden Gate assembly uses type II restriction enzymes, such as BsaI (Eco31I, 
Thermo Scientific, UK) and BpiI (BbsI, Thermo Scientific, UK) which cleave outside 
of their recognition sequence, leaving unique four-base flanking overhangs. Since 
recognition sites are located outside of the cleavage sites, after the digestion-ligation 
reactions these sites are eliminated, leading to directional, scarless cloning. In order to 
avoid undesired digestion, the recognition sites must not be present within the 
fragments that need to be assembled. This can be accomplished through PCR-
amplification of the fragments by using overlapping primers that introduce a single 
nucleotide mismatch at the BsaI/BpiI recognition sites. The domestication of the 
seven genes of the pleuromutilin gene cluster and of the plant selectable marker nptII, 
encoding an aminoglycoside phosphotransferase, which confers resistance to 
kanamycin, neomycin and Geneticin® G418, was performed by the PhD student 
Suphattra Sangmalee and the coding sequences of all seven genes of pleuromutilin 
pathway and nptII gene were provided in the Level zero form. Later in this project, 
the nptII gene was amplified from pISCL70004 plasmid (Golden Gate Plant Parts Kit, 
C11, specR) and correctly cloned into the Level zero acceptor for CDS1 modules 
pICH41308 (MoClo Plant Tool Kit, H2, specR). 
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2.4.2 Level generations 
The initial step of designing the complete multigene construct was planning 
the final form and the assembly strategy (Figure 2.1). This includes the final position 
and orientation of each transcription unit. Up to six transcription units can be cloned 
in a Level 2 construct at once, because no BsaI/BpiI sites are left after using one of the 
basic pELE-n end-linkers.  
 
Figure 2.1 Hierarchy of the modular cloning system. (A) Standard parts (Level 0) of promoters (P), 
5’ untranslated regions (U), signal peptides (SP), coding sequences (CDS) and terminators (T), which 
are further assembled to form a Level 1 transcription unit and finally multigene constructs. (B) 
Flanking sites of each Level 0 type module. (C) Example of two different transcription units encoding 




2.4.2.1 Level -1 
The purpose of a universal Level -1 (e.g. pAGM1311, MoClo Plant Tool Kit, 
A1, kanR) is to simplify the cloning of large Level 0 modules, while removing any 
internal BsaI/ BpiI sites. For smaller fragments, sequence domestication can be 
performed at Level 0. 
2.4.2.2 Level 0 
Level 0 plasmids consist of the standard parts which compose a transcription 
unit. These parts include promoters (P), 5’ untranslated regions (U), signal peptides 
(SP), coding sequences (CDS) and terminators (T). Level 0 destination vectors allow 
blue/ white selection, encoded by a lacZ gene and enabling E. coli to be resistant to 
Spectinomycin (specR). The MoClo Plant Tool Kit provides a series of different 
destination vectors according to the specific module type (e.g. promoters, coding 
sequences, terminators). The primers for PCR-amplified sequences were designed 
with a flanking overhang containing the BsaI or BpiI recognition site, following by 
the four unique nucleotides according to each module type. At this stage primers 
could be designed in a way enabling, in parallel, the removal of internal type IIS 
recognition sites as described above. 
2.4.2.3 Level 1 
 Appropriate combinations of compatible sets of Level 0 modules were 
assembled into a complete functional transcription unit (TU), giving each Level 1 
module (Figure 2.2). All Level 1 destination vectors were designed in order to provide 
a known position and orientation for TUs (position 1-7, forward or reverse 
orientation), making the customization of the final construct possible. Also, in 
contrast to Level 0 backbones, Level 1 cassettes harbor ampicillin/ carbenicillin 
resistance, while having in common a lacZ cassette for blue/ white selection. In order 
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to prevent the creation of too many Level 1 modules, the 7 destination vectors were 
designed to be used in a circular mode instead of a linear, by reusing the Level 1 
module for position 1 at a later virtual position 8, 15, 22 etc. The special feature of 
Level 1 vectors is the presence of both BpiI and BsaI sites, in order to compose the 
Level 1 (TU) module using the BsaI Golden Gate dig-lig reaction and leave intact the 
BpiI sites, outside the lacZ fragment and the BsaI sites, for a later assembly to give 
Level 2 multigene constructs (Figure 2.2).  
Figure 2.2 Example of a Level 1 Transcription Unit reaction with the unique 4bp overhangs for each 
Level 0 module. Pro35S: 35Spromoter from Cauliflower Mosaic Virus, GOI: gene of interest, nos: 
3'UTR, polyadenylation signal/ terminator nos (nopaline synthase) from A. tumefaciens. 
2.4.2.4 Level 2 
 Separate Level 1 modules (TUs) are then assembled together into multigene 
constructs by using the BpiI Golden Gate dig-lig reaction. All Level 2 acceptor 
vectors contain a red colour selectable marker (CRed, containing an artificial bacterial 
operon necessary for biosynthesis of b-carotene, which is visible, and its conversion 
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to the more visible on agar plates canthaxanthin, shown in red colour), which is 
flanked by two BpiI sites, and a resistance  gene for kanamycin (kanR). So, in this 
case, instead of a blue/ white selection there is a red/ white or a red/ blue selection in 
relation to pELE-1 to -7 (‘‘closed’’ construct; when there are no restriction sites left to 
add more modules) or pELB-1 to -7 (‘’open’’ construct; when the lacZ cassette is 
flanked by two BsaI sites and it is possible to add more modules) end-linker. There is 
also a third type of ‘’open’’ construct end-linker, the pELP-1 to -7, which enables the 
purple/ red selection by using the type IIS restriction enzyme, BsmBI, which was not 
used in this project. The different end-linkers allow the colour switching while adding 
more and more Level 1 TUs, still using the same Level 2 backbone that confers 
kanamycin resistance. 
2.4.2.5 Level M and Level P 
Level M destination vectors (specR) and end-linkers are used for pre-
assembling several Level 1 TUs, which can, then, be combined with other M Level 
constructs into Level P acceptor vectors (kanR), allowing the simultaneous high-
throughput creation of multigene constructs in one step (Figure 2.3). 
 
Figure 2.3 Relationship between Levels. Several Level 1 modules can be assembled into Level M, 
while several Level M modules can be assembled into Level P vectors. Boxes of Level 2-1, 2-2 and 2-3 
indicate that they are ‘’closed’’ constructs and further assembly cannot occur (Werner et al., 2012). 
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2.4.3 One pot digestion-ligation reaction 
One of the advantages of Golden Gate assembly is that multiple DNA 
fragments can be assembled in one-pot, digestion-ligation reaction (dig-lig), reducing 
the time required for the assembly of multigene constructs. The plasmids used from 
MoClo Plant Tool Kit and Golden Gate Plant Parts Kit are listed in Tables 2.4 and 
2.5, respectively.  
Table 2.4 List of destination and end-linker vectors used from MoClo Plant Tool Kit for Golden 
Gate Assembly. 
MoClo Plant Tool Kit 
Plate Pos. Vector Name Resistance Description 
H2 pICH41308 specR Level 0 acceptor for CDS1 modules 
A3 pICH41331 specR Level 0 acceptor for complete gene modules 
B3 pICH47732 carbR Level 1 acceptor. Position 1. Forward orientation 
C3 pICH47742 carbR Level 1 acceptor. Position 2. Forward orientation 
D3 pICH47751 carbR Level 1 acceptor. Position 3. Forward orientation 
E3 pICH47761 carbR Level 1 acceptor. Position 4. Forward orientation 
F3 pICH47772 carbR Level 1 acceptor. Position 5. Forward orientation 
G3 pICH47781 carbR Level 1 acceptor. Position 6. Forward orientation 
H3 pICH47791 carbR Level 1 acceptor. Position 7. Forward orientation 
A4 pICH47802 carbR Level 1 acceptor. Position 1. Reverse orientation 
H4 pAGM4673 kanR Level 2 acceptor 
B5 pICH41722 specR End-link 1 for assembling 1 Level 1 into Level 2 acceptor 
C6 pICH49277 carbR End-link 1 for assembling 3 Level 1 into Level 2 acceptor. 
With lacZ acceptor site 
D6 pICH49283 carbR End-link 1 for assembling 4 Level 1 into Level 2 acceptor. 
With lacZ acceptor site 
F6 pICH49300 carbR End-link 1 for assembling 6 Level 1 into Level 2 acceptor. 
With lacZ acceptor site 
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D8 pAGM8081 specR Level M acceptor. Position 6 
E8 pAGM8093 specR Level M acceptor. Position 7 
G8 pICH50881 carbR Level M end-link 2 
A9 pICH50900 carbR Level M end-link 4 
B9 pICH50914 carbR Level M end-link 5 
D9 pICH50932 carbR Level M end-link 7 
C10 pICH75388 kanR Level P acceptor. Position 7 
E10 pICH79264 carbR Level P end-link 2 
B11 pICH79311 carbR Level P end-link 7 
 
 
Table 2.5 List of Level 0 vectors (standard parts) used from Golden Gate Plant Parts Kit for 
Golden Gate Assembly. 





Module name and 4bp overhangs Module Description 
A3 pICH51277 GGAG_ProCaMV35SShort_5UTMV_AATG promoter (0.4 kb), 35s (Cauliflower 
Mosaic Virus) + 5'UTR, Ω 
(Tobacco Mosaic Virus) 
B3 pICH51288 GGAG_ProCaMV35SDouble_5UTMV_AATG promoter (double), 35s 
(Cauliflower Mosaic Virus) + 
5'UTR, Ω (Tobacco Mosaic Virus) 
D3 pICH87633 GGAG_Pro-AtuNos_5U-TMV_AATG promoter, nos, (A.tumefaciens) + 
5'UTR, Ω (TobaccoMosaicVirus) 
E3 pICH85281 GGAG_Pro-AtuMas_5U- AtuMas _AATG promoter + 5'UTR, mas, (A. 
tumefaciens) + 5'UTR 
F3 pICH88103 GGAG_Pro-AtuOcs_5U- AtuOcs _AATG promoter + 5'UTR, ocs, (A. 
tumefaciens) + 5'UTR 
G3 pICH87644 GGAG_Pro-AtAct2_5U-TMV_AATG promoter, act2 (AT3G18780, A. 
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resistance cassette (Nos promoter 
(A. tumefaciens) + nptII (E.coli) + 
Ocs terminator (A. tumefaciens)) 
F11 pICH41414 GCTT_3U+Ter-CaMV35S_CGCT 3'UTR, polyadenylation 
signal/terminator, 35s (Cauliflower 
Mosaic Virus) 
H11 pICH41421 GCTT_3U+Ter -AtuNos_CGCT 3'UTR, 
polyadenylationsignal/terminator, 
nos (A. tumefaciens) 
D12 pICH41432 GCTT_3U+Ter -AtuOcs_CGCT 3'UTR, polyadenylation 
signal/terminator, ocs (A. 
tumefaciens) 
 
The type IIS restriction enzymes BsaI (Eco31I) and BpiI (BbiI), and the T4 
DNA Ligase (5U/μl) were provided by Thermo Scientific, UK. PCR-amplified 
products were either cleaned from salts and enzymes or gel extracted before being 
added to the dig-lig reaction using the Nucleospin® Gel and PCR clean-up from 
Macherey-Nagel.  
To assemble fragments into Level 2 or Level M destination vectors, BpiI 
digestion was required, following the reaction: 
Acceptor plasmid 150ng 
Plasmid containing each part to be 
assembled 
2:1 molar ratio of insert:acceptor 
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10 units of BpiI 1μl 
10x Buffer G (with 0.1 mg/ml BSA) 2μl 
5 units of T4 DNA ligase (5U/µL) 1μl 
10x T4 DNA Ligase Buffer 2μl 
Sterile dH2O to 15μl 
Total volume 15μl 
 
To assemble fragments into Level 0, Level 1 or Level P destination vectors, 
BpiI digestion was required, following the reaction: 
Acceptor plasmid 150ng 
Plasmid containing each part to be assembled 2:1 molar ratio of insert:acceptor 
10 units of BpiI 1μl 
10x Buffer G (with 0.1 mg/ml BSA) 2μl 
5 units of T4 DNA ligase(5U/µL) 5μl 
10X T4 DNA Ligase Buffer 2μl 
Sterile dH2O to 15μl 
Total volume 15μl 
 
To assemble fragments into Level 2i (‘’open’’ construct) with a lacZ end-
linker, digestion with both enzymes, BsaI and BpiI, were required, following the 
reaction: 
Acceptor plasmid 150ng 
Plasmid containing each part to be assembled 2:1 molar ratio ofinsert:acceptor 
12.5 units of BpiI 1.25μl 
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7.5 units of BsaI 0.75μl 
10x Buffer G (with 0.1 mg/ml BSA) 2μl 
5 units of T4 DNA ligase (5U/µL) 1μl 
10X T4 DNA Ligase Buffer 2μl 
Sterile dH2O to 15μl 
Total volume 15μl 
 
The above reactions for Levels 0, 2i, 2, M and P were run in a PCR machine 
using the following program (Long protocol): 
37°C 20 seconds 
37°C 5 minutes        
16°C 5 minutes             
50°C 5 minutes 
80°C 10 minutes 
10°C Final storage 
Level 1 constructs were assembled using the short protocol: 
37°C 20 seconds 
37°C 3 minutes        
16°C 4 minutes             
50°C 5 minutes 
80°C 10 minutes 








2.4.4 Expression cassettes design schemes  
Four constructs were made for expression in M. polymorpha via 
Agrobacterium-mediated transformation, and another four for expression in P. patens 
via PEG-mediated homologous recombination transformation. All of the backbones 
derive from pBIN19 and pUC19, with ColE1 and RK2 origins of replication to 
replicate in both E. coli and Agrobacterium. 
The primers used for amplification of a part of Pp108 locus for homologous 
recombination in P. patens had additional recognition sites for PmlI (Eco72I, Thermo 
Scientific, UK), CAC^GTG, in order to leave blunt ends on both sides of each 
construct for PEG-mediated transformation and for BsaI, in order to ligate the PCR 
product into the Level 0 acceptor for making unit modules, pICH41331 (Table 2.6, 
Figure 2.4). 
Table 2.6 Primers used for amplification of approximately 1kb of Pp108 neutral locus from the P. 
patens genome. GGTCTC(1/5)^ in green colour indicate the recognition site of BsaI (Eco31I), and 
CAC^GTG in purple the recognition site of PmlI (Eco72I). L and R indicate the LB (Left Border) and 
RB (Right Border) of the vector. FF, forward primer; RR, reverse primer. 













Figure 2.4 Map of the Pp108 locus created using SnapGene®. This region was used for targeting 
homologous recombination of transgenes into P. patens genome. The coloured regions specify the 
regions amplified by PCR (~1-1.2kb) using the primer pairs listed above. BsaI/BpiI recognition sites 
were not present at the sequences selected for amplification. 
The selectable marker nptII gene was amplified from pISCL70004 and cloned 
into the Level zero acceptor for CDS1 modules pICH41308 using primers with 
flanking BsaI recognition sites: 
Table 2.7 Primers used for amplification of the new nptII coding sequence, GGTCTC(1/5)^ in 
green colour indicate the recognition site of BsaI (Eco31I). FF, forward primer; RR, reverse primer.  




pICHnptII or Level 1 empty vector (pL1empty) 
The empty vector construct contains only the plant selectable marker NPTII 
(Figure 2.5). 
pAGMggs:cyc:nptII or Level 2.2 (pL2.2) 
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This construct contains the first 2 genes encoding enzymes of the 
pleuromutilin pathway, geranylgeranyl pyrophosphate synthetase (GGS) and cyclase 
(CYC), and the plant selectable marker NPTII (Figure 2.5). 
pAGMggs:cyc:nptII:p1:p2:sdr or Level 2.5 (pL2.5) 
This construct contains the first 5 genes encoding enzymes of the 
pleuromutilin pathway, geranylgeranyl pyrophosphate synthetase (GGS), cyclase 
(CYC), two cytochrome P450s (P450-1, P450-2), a short-chain dehydrogenase/ 
reductase (SDR), and the plant selectable marker NPTII (Figure 2.5).  
 
pAGMggs:cyc:nptII:p1:p2:sdr:atf:p3 or Level 2.7 (pL2.7) 
This is the complete gene cluster construct encoding all seven enzymes of the 
pleuromutilin pathway, geranylgeranyl pyrophosphate synthetase (GGS) and cyclase 
(CYC), three cytochrome P450s (P450-1, P450-2, P450-3), a short-chain 
dehydrogenase/ reductase (SDR), an acetyl transferase (ATF), and the plant selectable 
marker NPTII (Figure 2.5).  
pAGMnptII_pp108.1 or Level M empty vector (pPpLMempty) 
The empty vector construct for homologous recombination in P. patens 
contains only the plant selectable marker NPTII and the homologous regions from 
locus pp108.1 from P. patens genome (Figure 2.6). 
pICHggs:cyc:nptII_pp108.1 or Level P.2 (pPpLP.2) 
This construct contains the first 2 genes encoding enzymes of the 
pleuromutilin pathway, geranylgeranyl pyrophosphate synthetase (GGS) and cyclase 
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(CYC), the plant selectable marker NPTII, and the homologous regions from P. 
patens (Figure 2.6). 
pICHggs:cyc:nptII:p1:p2:sdr_pp108.1 or Level P.5 (pPpLP.5) 
This construct contains 5 genes encoding enzymes of the pleuromutilin 
pathway, geranylgeranyl pyrophosphate synthetase (GGS), cyclase (CYC), two 
cytochrome P450s (P450-1, P450-2), a short-chain dehydrogenase/ reductase (SDR), 
the plant selectable marker NPTII, and the homologous regions from P. patens 
(Figure 2.7).  
pICHggs:cyc:nptII:p1:p2:sdr:atf:p3_pp108.1 or Level P.7 (pPpLP.7) 
This is the complete gene cluster construct encoding all seven enzymes of the 
pleuromutilin pathway, geranylgeranyl pyrophosphate synthetase (GGS) and cyclase 
(CYC), three cytochrome P450s (P450-1, P450-2, P450-3), a short-chain 
dehydrogenase/ reductase (SDR), an acetyl transferase (ATF), the plant selectable 




Figure 2.5 Modular Cloning (MoClo) for the construction of the plasmids used for M.  polymorpha and N. 
tabacum transformation. (A) Level 1 of the seven genes of pleuromutilin pathway and the selectable marker nptII. 
(B) Schematic of the modular cloning technique; Left column indicates the Level 1 modules, central column the Level 
2 destination vectors and end-linkers used, right column the final product of the digestion-ligation reaction. 
It is worth mentioning that another approach was followed, where a diversity 
of promoters and terminators was used to eliminate repetitious use that may lead to 
transcriptional gene silencing due to promoter methylation and inactivation (Peremarti 
et al., 2010). More specifically, transcriptional regulatory elements that were proven 
to be functional in all plant hosts of this project were chosen, shown in Table 2.8 and 
detailed in Table 2.5. 
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Table 2.8 Diversity of promoters and terminators used in multigene constructs. 
Gene ggs cyc nptII P450-1 P450-2 sdr atf P450-3 
Promoter 35S Act2 mas Act2 nos 35S mas 35S 
Terminator nosT 35ST oscT 35ST oscT nosT oscT nosT 
 
 
Figure 2.6 Schematic of the modular cloning technique of the plasmids designed for P. patens transformation. 
Left column indicates the Level 1 modules of the seven genes of pleuromutilin pathway, the selectable marker nptII 
and the two homologous regions of P. patens genome for homologous recombination, central column the new M 
destination vectors and end-linkers used, right column the final product of the digestion-ligation reaction. Note that 
pPpMempty uses the nptII Level 1 in position 1 and Pp108.1R Level 1 in position 2. Also, pPpLP.2 uses Pp108.1R 




Figure 2.7 Schematic of the modular cloning technique of the plasmids designed for P. patens 
transformation. Left column indicates the Level M modules detailed in Figure 2.6 that are combined, 
central column the new P destination vectors and end-linkers used, right column the final product of the 
digestion-ligation reaction. 
 
2.5 Molecular Techniques 
 
2.5.1 DNA extraction 
Total DNA from P. patens was isolated using a modified CTAB protocol 
(Doyle, 1991; Langlade Lab, University of Oxford, UK). 
Approximately 100mg of tissue was harvested, blotted on sterile Whatman 
paper, put in a 1.5ml Eppendorf tube and snap-frozen in liquid N2. Using a sterile cool 
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plastic pestle, the tissue was ground to a fine powder. 500µl of prewarmed extraction 
buffer were added and powder was ground further. Another 200µl extraction buffer 
(Table 2.9) were added to the mixture, along with 7µl 10mg/ml RNase A. The 
mixture was mixed by vortexing and incubated at 65° C for 10 minutes. Next, 600 µl 
chloroform-isoamyl alcohol (24:1) were added and the tube was shaken well. After 
spinning at 13,000g for 10 minutes, the upper aqueous phase was transferred to a new 
tube, 0.7x volume isopropanol was added to precipitate the DNA, and sample was 
immediately centrifuged at 13,000g for 10 minutes. The white pellet was washed with 
500μl of 70% cold ethanol and left on bench to air-dry. Finally, the pellet was 
resuspended in 15-30μl TE (10 mM Tris/ 1mM EDTA, pH 8.0) and 1-2μl (~200ng of 
plant gDNA) was used for each PCR. 
Table 2.9 Extraction Buffer used for CTAB DNA extraction method. 
Extraction Buffer*  
100 mM Tris-HCl pH8.0 25 ml  2M Tris-HCl pH 8.0 
1.42 M NaCl 142 ml 5 M NaCl 
2% CTAB 10 g CTAB 
20mM EDTA 20 ml 0.5M EDTA 
2% PVP-40 10g PVP-40 
dH2O to 500 ml 
*Extraction Buffer was filter sterilised, stored at RT and used within 2-3 days, after prewarming at 
65°C. 7μl of beta-mercaptoethanol and 10mg ascorbic acid were added to 10ml buffer immediately 
before use. 
 
2.5.2 RNA extraction 
Isolation of total RNA was performed using the TRIzol® reagent provided by Thermo. 
a) Cell lysis and separation of phases 
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The tissue of plants was ground to a fine powder and 50-100mg was added 
into microcentrifuge tubes along with 1ml of cold TRIzol reagent for each sample. 
After rigorous mixing the tubes were incubated at room temperature for 5 minutes. 
Next, 200μl of chloroform were added, tubes were stored at room temperature for 2-3 
minutes and centrifuged for 15 minutes at 12,000g at 4°C. The aqueous phase 
containing the RNA was transferred to a new tube. 
b) Isolation of RNA 
Into the aqueous phase, 500μl of isopropanol were added and tubes were 
stored at room temperature for 10 minutes. Then they were centrifuged for 10 minutes 
at 12,000g at 4°C. The supernatant was discarded and the white gel-like pellet was 
resuspended in 1ml of 75% ethanol. After mixing the tubes briefly, they were 
centrifuged for 5 minutes at 7,500g at 4°C. The supernatant was discarded and the 
RNA pellet was air dried for 10 minutes. The pellet was resuspended in 50μl sterile 
dH2O and incubated in a water bath at 60°C for 15 minutes, before being stored at -
70°C. 
2.5.3 DNase treatment 
Removal of genomic DNA from RNA was performed using DNase I and RiboLock 
RNase Inhibitor from Thermo by adding the following components to an RNase-free 
tube: 
Total RNA of each sample 1μg 
10x reaction buffer with MgCl2 1μl 
DNase I  1μl 
RiboLock RNase Inhibitor 0.5μl 
Sterile dH2O to 10μl 
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Total volume 10μl 
 The above reaction was run according to the following program: 
37°C 30 minutes* 
65°C 10 minutes 
*Note that the program was paused, tubes were immediately transferred on ice and 
1μl of 50mM EDTA was added. The program continued to reach 65°C, then was 
paused again and tubes were placed back into the thermal cycler. 
 
2.5.4 Plasmid extraction 
2.5.4.1 E. coli small-scale plasmid extraction 
Colonies of E. coli obtained after transformation were grown overnight at 37°C 
and shaking at 200rpm by inoculating them in LB broth supplemented with the 
appropriate antibiotic/reagents as indicated at Table 2.1. Plasmid extraction for Level 
2i-1, 2, M and P was performed using the NucleoSpin® Plasmid kit by Macherey-
Nagel following the manufacturers’ protocol for high-copy plasmid DNA isolation 
from E. coli.  
2.5.4.2 E. coli alkaline lysis small-scale plasmid extraction 
Plasmid extraction of the initial Level 0 and Level 1 constructs was conducted 
using a modified alkaline lysis based protocol, using homemade buffers (Birnboim & 
Doly, 1979). According to this protocol, the liquid culture was centrifuged in 1.5ml 
Eppendorf tube 2-3 times. After discarding all the supernatant, the pellet was 
resuspended in 300μl P1 Buffer (50mM Tris/ 10mM  EDTA, pH 8.0) supplemented 
with RNase A (3mg/ml or 3μl per sample of 10mg/ml stock RNase A (#EN0531, 
Thermo Scientific, UK) and was vigorously shaken until it resuspended. Then, 300μl 
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P2 Buffer (200mM NaOH/ 1% (w/v) SDS) were added and the tube was inverted 
gently until suspension became clear. Next, 300μl P3 Buffer (3M Potassium 
acetate/~10% (v/v) Glacial acetic acid/pH 5.5) were added, the tube was inverted 
again and left on ice for 10 minutes. The cell debris, proteins and chromosomal DNA 
were pelleted by centrifugation at full speed for 10 minutes. The supernatant was 
transferred into a clean 1.5ml Eppendorf tube, 600μl Isopropanol were added and the 
tube was centrifuged at full speed for 15 minutes for plasmid DNA precipitation. 
After spinning, the supernatant was carefully discarded, and the DNA pellet was 
washed with 700μl of 70% ethanol. After centrifugation at full speed for 10 minutes, 
the ethanol was carefully removed, and the tubes were incubated at 37°C for 10 
minutes to accelerate the evaporation of any residual ethanol. Finally, the pellet was 
resuspended in 20μl sterile deionized H2O. 
2.5.4.3 E. coli large-scale plasmid extraction 
 Higher concentrations of the plasmids were needed for the PEG-mediated 
transformation of P. patens protoplasts. The NucleoBond®Xtra Midi kit from 
Macherey-Nagel was used in this case, according to manufacturers’ protocol using a 
starter culture of 100ml and OD600 =4. 
2.5.4.4 A. tumefaciens plasmid extraction 
Plasmid extraction from A. tumefaciens was performed using Nucleospin®Plasmid 
by Macherey-Nagel kit for low-copy plasmids, according to a supplementary protocol 
provided by the manufacturers. The initial liquid culture was inoculated with one 
unique colony for screening in 4ml of YEB medium (5g/l tryptone, 1g/l yeast extract, 
5g/l nutrient broth, 5g/l sucrose, 0.49g/l MgSO4·7H2O) supplemented with 
rifampicin/streptomycin and kanamycin or carbenicillin for 36-48 hours at 28°C. The 
liquid culture was centrifuged in 2ml tubes at 14,000 x g for 1 minute and, then, 
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resuspended in 1ml Wash Buffer (1M NaCl). The mixture was centrifuged at 14,000 x 
g for 1 minute, cells were resuspended in 200μl Lysis Buffer (25Mm Tris-HCl, 10mM 
EDTA, pH 8.0, 50mM glucose, 50mg/ml lysozyme) and were shaken for 30 minutes 
at 37°C, for total digestion of the cell wall. The tube was filled to a total volume of 
500μl with Resuspension Buffer A1 provided by the kit and the protocol for low-copy 
plasmids continued from cell lysis step. 
2.5.5 Restriction Digest 
The restriction enzymes used in this project were provided by Thermo 
Scientific, UK, and are listed below: 
Table 2.10 Restriction enzymes used in digest for screening of the plasmids isolated. All were in 















The reaction below was incubated at 37°C for 30 minutes before gel 
electrophoresis: 
10X FastDigest Green Buffer 2μl 
FastDigest enzyme 1μl 
Plasmid DNA 1μl (up to 1μg) 
Sterile H2O 16μl 
Total volume 20μl 
 
 
2.5.6 Polymerase Chain Reaction (PCR) 
PCRs for screening the presence of the genes were performed using the 
DreamTaq Green DNA Polymerase (#EP0711, Thermo Scientific, UK) by adding the 
following components for each 50μl reaction: 
10x DreamTaq Green Buffer (20mM MgCl2) 5μl (1x) 
10mM dNTPs 1 (0.2mM of each) 
Forward primer 1.0 μM 
Reverse primer 1.0 μM 
Template DNA ~10pg for plasmid DNA/ 
~200ng for plant gDNA 
DreamTaq DNA Polymerase 0.025U/μl 
Sterile dH2O to 50μl 
Total volume 50μl 
 
The above reaction was run for 35 cycles, according to the following program: 
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95°C 2 minutes 
95°C 30 seconds 
50-60°C* 30 seconds             
72°C 1 minute 
72°C 10 minutes 
10°C Final storage 
*Note that for the primer annealing step the Ta (annealing temperature) was calculated 
typically 5°C to 8°C below Tm (melting temperature) of each primer. 
The primers used for the 7 genes of the pathway, plus the selective marker are 
listed below:  
Table 2.11 Primers used for amplification of gene fragments. FF, forward primer; RR, reverse 
primer; reg, regular. 























PCRs for amplification of the nptII coding sequence from pICSL70004 and of 
the homologous regions from wild-type P. patens DNA samples were conducted 
using the Phusion Green High-Fidelity DNA Polymerase (#F-534L, Thermo 
Scientific, UK), according to the following 50μl reaction: 
5x Phusion Green HF Buffer (1.5mM MgCl2) 10μl (1x) 
10mM dNTPs 1 (0.2mM of each) 
Forward primer 1.0 μM 
Reverse primer 1.0 μM 
Template DNA ~10pg for plasmid DNA/ 
~200ng for plant gDNA 
Phusion DNA Polymerase 0.02U/μl 
Sterile H2O to 50μl 
Total volume 50μl 
 
 
This reaction was run based on a modified version of Touchdown PCR 
(Bounce PCR V.3) that facilitates the amplification when using primer-extension 









68°C 15 seconds / 1.0°C decrease 
72°C 1 minute 
98°C 20 seconds 
53°C 15 seconds / 0.6°C increase 
72°C 1 minute 






All the PCR reactions were conducted in the thermal cycler PCR max Version 
2.41 or the BioRad T100. 
 
2.5.7 Quantitative Reverse Transcription PCR (RT-qPCR)  
Relative expression levels of the 7 genes in M. polymorpha were compared to 
empty vector control samples. For normalization, actin7 expression levels were also 
analyzed. Luna® Universal One-Step RT-qPCR kit from New England BioLabs was 
used, which combines in silico reverse transcription (RT), using the Luna WarmStart 
Reverse Transcriptase (cDNA synthesis) and then amplification, using the Hot 
Start Taq DNA polymerase. For quantification after each PCR cycle, SYBR Green I 










Figure 2.8 SYBR Green Dye during amplification. Fluorescence increases 100 to 200-fold when 
bound to double-stranded DNA (Fraga et al., 2008). 
 
Figure 2.9 Graph of the amplification plot, standard curve and melt curve of th RT-qPCR using 
Luna® kit. The horizontal line of the amplification plot indicates the threshold line where fluorescence 
signal is produced. The threshold cycle (Ct) demonstrates the amplification cycle where fluorescence 
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exceeds the baseline. The cycle of quantification value (Cq) is the PCR cycle which the sample 
intersects the threshold line. A range of input concentrations was used (0.1pg-1μg) with 8 replicates of 
each concentration. NTC used as a non-template control. Melt curve shows the change in fluorescence 
when double-stranded DNA dissociates to single-stranded DNA due to temperature rise (product # 
E3000L, adapted from NEB.com). 
 
Relative expression levels were calculated using Microsoft® Excel 2007 
according to the ΔΔCt method (Zhang et al., 2015), using the following equation: 
Amount of target or REU* = 2 –ΔΔCt 
Average Test 
 Ct value 
Average Test  
Ct value 




TE HE TC HC 
ΔCt value (Test)  ΔCt value (Control)  
TE-HE  TC-HC  
ΔΔCt = ΔCt value (Test) - ΔCt value (Control) 
*REU stands for Relative Expression Units that were displayed as fold change 
relative to control samples. TE is the average Ct value for the gene being tested and 
HE for the housekeeping gene, both under experimental conditions. TC is the average 
Ct value for the gene being tested and HC for the housekeeping gene, both under 
control conditions. 
The Luna® reaction was conducted using the CFX Connect Real-Time PCR 
Detection System by Bio-Rad and data were obtained using the CFX Maestro 
Software. The components of the RT-qPCR reaction were the following: 
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Reaction mix (2x) 5μl (1x) 
WarmStart reverse transcriptase 0.5μl 
Forward primer 0.4μl 
Reverse primer 0.4μl 
Template RNA ≤1μg 
Sterile dH2O to 10μl 
Total volume 10μl 
 
The primers used are listed in Table 2.12. The above reaction was run 
according to the following program: 
 
 
Table 2.12 Primers used for qPCR and sequencing. FF, forward primer; RR, reverse primer; q, 
qPCR; seq, sequencing. 







55°C 10 minutes 
95°C 1 minute 
95°C 10 seconds 
60°C 30 seconds 





















2.5.8 Gel electrophoresis 
Agarose gels 1% (w/v) in TAE were used for visualising DNA using a UV 
transilluminator. Agarose powder was solved in 1x TAE Buffer (50x TAE: Tris-
acetate 40mM/ pH 7.5, glacial acetic acid 20mM, Na2EDTA 1mM/ pH 8.0), including 
Midori Green Advance DNA stain (Nippon Genetics, Europe GmbH), heated in a 
microwave and poured into a mould with appropriately spaced combs to form sample 
wells. Where needed, samples were mixed with 1x Loading Dye (6x DNA Loading 
Dye: glycerol 50% (v/v), 50x TAE 2% (v/v), bromophenol blue 0.25% (w/v), xylene 
cyanol 0.25% (w/v), RNA Loading Dye: formamide 95% (v/v), SDS 0.025% (w/v), 
0.5mM EDTA, bromophenol blue 0.025% (w/v), xylene cyanol 0.025% (w/v)), 
loaded on gel lanes and run at 120V in Bio-Rad horizontal gel tanks. Results were 
obtained with the Bio-Rad ChemiDoc XRS+® or Gel Doc EZ®, using the ImageLab® 
software. 1kb Plus DNA Ladder (2-log DNA Ladder) from New England BioLabs 




Figure 2.10 5μl of 1kb Plus DNA Ladder visualised by ethidium bromide staining on a 1% (w/v) 
TBE agarose gel (product #N3200S, adapted from NEB.com). 
2.5.9 PCR product purification 
NucleoSpin® Gel and PCR Clean-up kit from Macherey-Nagel was used for 
removal of salts, enzymes and primer dimers from PCR reactions following the 
manufacturers’ protocol. 
2.5.10 Gel extraction 
The desired bands were cut from 1% (w/v) agarose gels which were run at 
60V for 25 minutes in order to lower the temperature during electrophoresis and the 
UV exposure was applied at the longest wavelength possible to avoid damaging the 
DNA. NucleoSpin® Gel and PCR Clean-up kit from Macherey-Nagel was used 
following the manufacturers’ protocol. 
2.5.11 DNA sequencing 
DNA sequencing was conducted by Source BioScience in Cambridge, UK. 
The primers used for sequencing of the genes are listed at Table 2.12 and the primers 
used for the old nptII  Level 1 plasmid are listed below: 
Table 2.13 Primers used for amplification of the old nptII Level 1 transcription unit. FF, forward 
primer; RR, reverse primer; seq, sequencing. 
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2.5.12 Quantification of nucleic acids 
The purity and concentration of isolated nucleic acids was estimated using the 
NanoPhotometer® N60/N50 provided by Implen. 
 
 2.6 Preparation of competent bacterial cells 
2.6.1 Chemically competent E.coli (‘’Ultra-competent’’ cells by Inoue method) 
(Im et al., 2011; Inoue et al., 1990) 
a) Preparation of cells 
Inoue transformation buffer (10.88g/l MnCl2.4H2O, 2.2g/l CaCl2.2H2O, 
18.65g/l KCl, 0.5M PIPES/ pHKOH 6.7, H2O to 1l) was filter sterilised and chilled 
before use. A single bacterial colony was picked from a freshly streaked plate and 
grown at 37°C into 25ml of LB Broth in a 250ml flask for 6-8 hours. Three 1L flasks 
were inoculated with the starter culture, each containing 250ml of LB broth. The first 
was inoculated with 2ml, the second with 4ml and the third with 10ml. All three 
flasks were incubated overnight at 20°C and shaking at 100rpm. The following 
morning the OD600 was measured every 45 minutes until one of the cultures reached 
OD=0.55. This culture was immediately transferred into an ice-cold water bath for 10 
minutes. The culture was poured into 50ml Falcon® tubes and centrifuged at 2,500 x g 
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for 10 minutes at 4°C. After complete removal of the medium, the cells were 
resuspended in 80ml of ice-cold Inoue transformation buffer, mixed gently in the cold 
room (4°C) and harvested by centrifugation at 2,500 x g for 10 minutes at 4°C. 
 
b) Freezing of competent cells 
After the last centrifugation the supernatant was discarded and the cell pellet 
was resuspended in 20ml of ice-cold Inoue transformation buffer. Then, 1.5ml of 
DMSO was added into the suspension, the bacterial cells were mixed and then 
incubated on ice for 10 minutes. Finally, the bacterial suspension was dispensed into 
aliquots of 50μl, immediately snap-frozen in a bath of liquid nitrogen and stored at -
70°C until needed. 
 
2.6.2 Electro-competent E. coli 
 A single colony was picked from a streaked plate and grown in 5ml LB broth 
overnight at 37°C and 200rpm. The next day the 5ml culture was transferred into 
100ml liquid LB broth at the same conditions until OD600 reached 0.4-0.6. The culture 
was poured into two 50ml centrifuge tubes and placed on ice for 10 minutes. The cells 
were pelleted at 4,000 x g for 10 minutes at 4°C and resuspended in pre-chilled sterile 
H2O. At this step 15ml H2O were added to each tube and the content of both tubes 
was merged. The one tube containing both cell pellets was filled up to 50ml with H2O 
and the cells were resuspended. The cells were centrifuged at 4,000 x g for 10 minutes 
at 4°C and the previous resuspension step was repeated. After the second 
centrifugation, the supernatant was removed and the cells were resuspended in pre-
chilled glycerol solution 10% (w/v) (4ml per tube) and centrifuged at the same 
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conditions. The final pellet was resuspended again in pre-chilled glycerol solution 
10% (w/v) (250μl per tube), dispensed in 40μl aliquots, flash-frozen in liquid nitrogen 
and stored at -70°C until use. 
2.6.3 Chemically competent A. tumefaciens 
 One single colony was inoculated in 5ml YM broth containing the appropriate 
antibiotics. The next day, 2ml of the overnight culture were added to 50ml YM Broth 
in a 200ml flask and grew until OD600 reached 0.6. The culture was left on ice for 15 
minutes and centrifuged at 3,000 x g at 4°C for 5 minutes. The cells were resuspended 
in 1ml of 20mM CaCl2 solution and dispensed in 100μl aliquots into pre-chilled tubes. 
Finally, the tubes were flash-frozen into liquid N2 and stored at -80°C until use (An et 
al., 1988). 
 
2.6.4 Electro-competent A. tumefaciens 
LBA4404 A. tumefaciens glycerol stock was streaked on a plate with YM 
media, supplemented with 20μg/ml rifampicin and 100μg/ml streptomycin (Table 
2.1). After 2-3 days growth on plates, 5ml of YM liquid media was inoculated with 
one single colony containing the appropriate antibiotics and incubated at 28°C with 
agitation at 200rpm. Six hours later three 150ml cultures were inoculated with 1ml 
each of the 5ml culture and grown for 30-40 hours. When OD600 reached 0.8-1.0 the 
cultures were put on ice for 15 minutes. All next steps were performed on ice. 
Cultures were distributed to 8x50ml tubes and centrifuged at 4,000 x g for 30 minutes 
at 4°C. The pellets were washed with 10ml sterile ice cold dH2O and filled up to 50ml 
with dH2O. The above centrifugation step was repeated and pellets were washed again 
with 10 ml ice cold dH2O. The solutions were combined into 4x50ml tubes and filled 
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up with dH2O to 50ml. Another centrifugation step was conducted and pellets were 
dissolved in 10ml ice cold dH2O, combined to 2x50ml tubes and filled up to 50ml 
with dH2O. The tubes were centrifuged again and the pellets were resuspended with 
10ml ice cold dH2O, and then combined to 1x50ml tube. A final centrifugation step 
was performed, the cell pellet was resuspended in 4.5ml ice cold 10% glycerol, 
dispensed into 80μl aliquots, flash-frozen in liquid N2 and stored at -80°C until use. 
 
2.7 Transformation of bacterial cells 
2.7.1 Chemical transformation of E.coli 
 Into each aliquot of competent cells, 5-10ul of ligation reaction or plasmid 
were added, and the tube was flicked and left on ice for 40 minutes. A heat-shock 
treatment at 42°C was applied for 60 seconds and cells were recovered by short 
incubation on ice then addition of 1ml prewarmed LB broth without antibiotics. The 
tubes were incubated for 1 hour at 37°C to allow the cells with the new plasmid to 
express resistance and then plated into LB plates containing the appropriate 
antibiotics. 
2.7.2 Electroporation of E. coli 
 Aliquots of electro-competent cells were thawed on ice and 1-2μl of ligation 
reaction or plasmid was added. The mixture was loaded into a pre-chilled 0.2cm 
cuvette and 2.5kV electric pulse was applied for 5msec using the MicroPulser 
Electroporator by BioRad (Setting ‘’Ec2’’). Immediately after electroporation, 1ml of 
pre-warmed LB broth was added and the cuvette content was transferred back to the 




2.7.3 Chemical transformation of A. tumefaciens 
Agrobacterium aliquots were thawed on ice and up to 10μl plasmid (100-
1000ng) were added. The tube was mixed, kept on ice for 5 minutes and then 
transferred into liquid N2 for 5 minutes. The tubes were incubated for 5 minutes in a 
water bath of 37°C. Then, 1ml LB medium was added and the tubes were left at 28°C 
for 3 hours for cells to recover, before plating them on selective YM media. 
 
2.7.4 Electroporation of A. tumefaciens 
Plasmid DNA (0.1-0.5μl) was added to an 80μl Agrobacteria aliquot, the tube 
was mixed and loaded into a 0.1cm cuvette. A pulse of 2.2kV was delivered using the 
MicroPulser Electroporator by BioRad (Setting ‘’Agr’’) and immediately 500μl SOC 
media (For 100ml SOC: 99ml SOB, 1ml 2M glucose solution; SOB: 0.5g/l NaCl, 
20g/l Tryptone, 5g/l Yeast Extract) were added into the cuvette. The mixture after 
being transferred back to the tube, was incubated for 2-3 hours at 28°C, before plating 
on selective YM media. 
2.8 Agro-infiltration of Nicotiana tabacum (Li, 2011) 
a) Preparation of Agrobacterium culture 
After streaking Agrobacteria glycerol stocks on YM plates and incubation at 
28°C for 2-3 days, a single colony was used to inoculate 5ml YM Broth medium with 
20μg/ml rifampicin, 100μg/ml streptomycin and 50μg/ml kanamycin (pL2.2, pL2.5, 
pL2.7) or 75μg/ml carbenicilin (pL1empty) and incubated overnight at 28°C with 
agitation at 200rpm. The next day, 1ml of the starter culture was used to inoculate 
25ml LB with the same antibiotics, plus 20μM acetosyringone and grown overnight. 
The third day, the OD600 of the culture was measured and the culture was centrifuged 
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at 5,000 x g for 15 minutes. The pelleted cells were resuspended in Resuspension 
Solution (10mM MgCl2, 10mM MES-K/ pH 6.6 with KOH, with filter-sterilized 
100μM acetosyringone added after autoclaving of the solution and immediately 
before use) to reach a final OD600 of 0.4. The cells were stored at room temperature 
for 2-3 hours before infiltration. 
b) Infiltration of N. tabacum 
Leaves of approximately 5-week-old N. tabacum were used for infiltration, 
while the same leaf was infiltrated for each technical replicate to achieve the same 
developmental stage. Using a 5ml syringe without needle, the mixture containing the 
transformed Agrobacteria was infiltrated by placing the syringe on the underside of 
the leaf and applying a counter-pressure to the upper side of the leaf with the gloved 
fingers. Successful filling of the apoplastic spaces with the bacterial solution became 
visible by a dark-green pattern (‘’wetting’’ area). After infiltration, the plants were 
grown for a week post-infiltration in a plant incubator at 25°C, 16hr light/ 8hr dark, 
60% humidity and 100μmol/m2s light intensity, and leaves were harvested for 
screening, 3, 5 and 7 days post-infection (d.p.i). 
 
2.9 Stable transformation of Marchantia polymorpha 
Transformation of M. polymorpha was performed by following an 
Agrobacterium-mediated transformation protocol using regenerating thalli (Kubota et 
al., 2013). According to this protocol, 14-day-old thalli were cut across the apical-
basal axis, about 2-3mm from the tip, including the meristem. Thallus regeneration 
was accomplished by incubating cut thalli on a half strength Gamborg’s B5 medium 
supplemented with 1% (w/v) sucrose for 3-7 days under normal growth conditions 
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(Section 2.2.2). In the meantime, A. tumefaciens strain LBA4404 harboring each 
plasmid (Section 2.4.4) was inoculated in a starter culture of 5ml 2 days before co-
cultivation. On the day of co-cultivation, the bacterial cells were harvested by 
centrifugation, resuspended in 5 volumes of 0M51C medium (Table 2.14) 
supplemented with 100μM acetosyringone, and incubated for 6 hours at 28°C and 200 
rpm. After 6 hours, approximately 20 regenerating plantlets and 1ml of 
Agrobacterium culture, as described, were co-cultivated in 50ml of 0M51C medium 
supplemented with 2% (w/v) sucrose and 100μM acetosyringone into 200ml flasks 
for 3 days under normal growth conditions (Section 2.2.2) and agitation at 130rpm. 
Next, the thalli were washed 5-6 times with sterile dH2O and left to soak in sterile 
dH2O containing 1g/l cefotaxime to prevent Agrobacterium growth. After 30 minutes, 
the plantlets were transferred into half strength Gamborg’s B5 medium supplemented 
with 1% (w/v) sucrose, 100mg/l cefotaxime and 5mg/l G418 (Geneticin®, Santa Cruz 
Biotechnology, USA). Geneticin-resistant thalli became distinct 15 days after transfer 
to the selective media, whereas the original cut thalli became necrotic. Isogenic lines 
were obtained after 2 cycles of transplantation of gemmae (G2 generation), which 
were used for analyses (Figure 2.11). 
Table 2.14 0M51C medium used for M. polymorpha transformation. 10x stock was autoclaved 
without B5- micro components or B5-vitamin, which were filter sterilised and added after autoclaving. 
L-glutamine, casamino acids, sucrose and acetosyringone were also filter sterilised and added before 
use. 
0M51C medium (1l pH 5.5 with 1N KOH)  
10x 0M51C stock 100ml 
0.03% (w/v) L-glutamine 0.3g 
0.1% (w/v) casamino acids 1g 
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B5-micro components 40ml 
B5-vitamin 40ml 
KI solution (750mg/100ml) 4ml 







B5-vitamin (100ml store at -20°C)  
Inositol 10g 







Figure 2.11 Transformation of M. polymorpha regenerating thalli. (A) A 14-day-old thallus indicated by the 
parts that are being cut. (B) Fragments after thallus cutting on half strength Gamborg’s B5 supplemented with 1% 
(w/v) sucrose. (C) After 3-7 days of regeneration, thalli were co-cultivated with Agrobacterium in 0M51C medium 
containing 100μM acetosyringone for 3 days. Two weeks later, resistant thalli became distinct while the original 
thalli became necrotic. Scale bars represent 1mm (A) and 5mm (B-C). 
 
 
2.10 Stable transformation of Physcomitrella patens (Schaefer et al., 1991) 
a) DNA preparation 
Plasmid DNA was isolated using the NucleoBond®Xtra Midi kit from 
Macherey-Nagel. 100μg plasmid DNA was digested using 100u (or 10μl) PmlI 
enzyme (Thermo Scientific, UK). The cut plasmid was precipitated, cleaned and 
dissolved in 100μl dH2O, with a final minimum concentration of 500ng/μl. 
b) Tissue preparation 
 Tissue was prepared by culturing P. patens plant homogenised with the T10 
basic ULTRA-TURRAX® homogeniser, IKA, UK, in sterile dH2O onto 2 BCD-AT 
plates overloaded with cellophane disks. After growing for 5 days, tissue from each 
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plate was passaged again and split onto 2 plates. This procedure was repeated 3 times, 
every 4-5 days. 
c) Protoplast isolation 
250mg Driselase® (Sigma, UK) was dissolved in 25ml 8.5% (w/v) mannitol, 
mixed by shaking for 20 minutes and filter sterilised into a new falcon tube. The 
tissue was collected from 4-6 cellophane plates and added into the previous 25ml 
solution. The mixture was placed in the dark for 30 minutes with gentle mixing every 
5-7 minutes, and filtered through a sterile cell strainer 70μm (Fisherbrand, UK) into a 
new sterile petri dish. The mixture was filtered again into a second petri dish and then 
transferred into a sterile test tube 100x16mm with a cap (VWR, UK). The cells were 
pelleted by centrifugation at 600xg for 5 minutes, resuspended into 10ml 8.5% (w/v) 
mannitol and centrifuged again. Previous resuspension and centrifugation steps were 
repeated two more times. 
d) Protoplast PEG-mediated transformation 
 Using a haemocytometer, protoplasts were counted and resuspended to a 
concentration of 1.6x106/ml in MMM solution (Table 2.15). 10-15μg DNA in 
maximum 30μl dH2O was dispensed in each new transformation tube. 300μl 
protoplasts in MMM solution were added and mixture was mixed gently. Next, 
another 300μl PEG solution was added and heat-shock at 45°C for 5 minutes was 
applied. The tubes were left for 5 minutes at room temperature before adding 1ml of 
protoplast liquid media. The tubes were set for 5 minutes and 2ml of protoplast liquid 
media were added. After waiting a further 5 minutes, 3ml of protoplast liquid media 
were added and mixture was poured into small petri dishes, wrapped in foil, sealed 
with micropore tape and kept overnight at growth chamber. The next day, the 
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protoplasts were centrifuged at 600xg for 5 minutes and resuspended into 8ml 
PRM/T. These 8ml were then plated out onto 4 regeneration plates PRM/B with 
cellophane discs and sealed with micropore tape. After growing in chamber for 7 days 
the protoplasts that had survived were transferred to selection plates containing 
25mg/l G-418. After 10 days the resistant colonies were then transferred onto plates 
without selection for further 10 days and finally a small amount of tissue was 
propagated back onto selective plates. 
Table 2.15 Solutions used for the PEG-mediated transformation of P. patens protoplasts. 
Solutions B, C, D, AT and TES detailed in Table 2.2. 
Transformation solutions   
MMM solution (20ml) 1M MgCl2 300μl 
 1% (w/v) MES/ pHKOH 5.6 2ml 
 mannitol 1.7g 
PEG solution (10ml) 8.5% (w/v) mannitol 8.2ml 
 1M Ca(NO3)2 1ml 
 1M Tris/ pH 7.2 100μl 
 molten PEG 6000 3.5g 
Protoplast liquid media (100ml) stock A*, B, C, AT 1ml 
 mannitol 6.6g 
 glucose 0.5g 
 *A: 118g.l Ca(NO3)2.4H2O, 
1.25g/l FeSO4.7H2O 
 
PRM/B (500ml) stock B, C, D, AT 5ml 
 1x TES 500μl 
 mannitol 30g 
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 CaCl2.2H2O 0.935g 
 Agar 4g 
PRM/T (100ml) stock B, C, D, AT 1ml 
 1x TES 100μl 
 mannitol 8g 
 CaCl2.2H2O 0.145g 
 Agar 0.7g 
 
2.11 Metabolite extraction from plant material 
The plant tissue was snap-frozen in liquid nitrogen and ground to a fine 
powder. When tobacco leaves were harvested, the leaf midvein was discarded. The 
ground tissue was transferred to 2ml tubes and 1.5ml of 40% aqueous methanol 
(MeOH), containing 0.5% acetic acid was added. The tubes were mixed vigorously 
for 2-3 minutes and were sonicated for 20 minutes. After centrifugation at 12,000xg 
and 4°C for 15 minutes, the supernatant was transferred into a glass vial, vacuum 
dried and pellet was resuspended in 100μl acetonitrile. 
2.12 LCMS analysis 
LCMS analyses were run using a Waters system, with a Waters 2767 
autosampler, Waters 2545 pump system and a Phenomenex Kinetex column. The 
Diode Array detector between 200 and 600nm was by Waters 2998. ES+ and ES- 
were operating by a Waters 2424 ELSD and Waters SQD-2 mass detector between 
100 m/z and 800 m/z (de Mattos-Shipley et al., 2018). Data were visualized using the 
Waters MassLynx V4.2 SCN982 software. Solvents were a linear 5%-95% gradient 




2.13 Bioinformatics software 
For the visualization of construct maps, digestion profiles and sequencing data 
Benchling® and SnapGene® were used. Known sequences were downloaded from the 
National Center for Biotechnology Information (NCBI) library. BLAST® (Basic 
Local Alignment Search Tool) and primer design tool were also conducted on NCBI 
site. Sequences of the genes and the final plasmids are shown in FASTA format in 
Appendix A. 
 
2.14 Microscopic observation and image processing 
Observation of plants was performed with LEICA® M205 C, LEICA® DMLB 
and GX® stereo microscope XTC series, using the GX Capture software. Photos were 
taken using a Canon® PowerShot A3300 IS, image processing and analyzing was 









Chapter 3: Construction of plasmids 
 
 3.1 Aims  
In order to build the pleuromutilin biosynthetic gene cluster in different plant 
species, the genes of the pathway were cloned using the Golden Gate system, using 
promoters and terminators that are functional in the several plant species (see Section 
2.4).  The empty vector construct contains only the plant selectable marker gene of 
neomycin phosphotransferase II (nptII), which provides resistance to geneticin, 
kanamycin or neomycin. The construct containing the first 2 genes of the pathway, 
geranylgeranyl pyrophosphate synthetase (ggs) and cyclase (cyc) also contains the 
nptII marker. The 5-gene construct consists of ggs, cyc, two cytochrome P450s (p450-
1, p450-2), a short-chain dehydrogenase/ reductase (sdr), and the plant selectable 
marker nptII. The complete gene cluster construct, encoding all seven enzymes of the 
pleuromutilin pathway, contains the genes ggs, cyc, p450-1, p450-2, p450-3, sdr, an 
acetyltransferase (atf) and the nptII marker. For P. patens homologous 
recombination, the same combination of genes was used and the homologous regions 
from locus Pp108.1 from P. patens genome were cloned bilaterally between the 
transcription units. 
 
3.1.1 Level 0 plasmids 
 Prior to commencing this research, level zero plasmids containing cDNA of 
each of the coding sequences of all seven genes of pleuromutilin pathway and nptII 
were generated by Suphattra Sangmalee a previous student within the group. These 
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had also been modified to remove all internal BsaI/BpiI sites as these would interfere 
with the Golden Gate cloning system.  
Prior to their use, the L0 plasmids were confirmed by restriction digests with 
BsaI (Figure 3.1). In all cases the expected digest pattern was obtained confirming 
that they were correct and that the internal BsaI sites had indeed been removed. 
Specific compatible sets of Level 0 modules were ligated into a complete functional 
transcription unit (TU), giving each Level 1 module. All Level 1 vectors are able to 
promote a known position and orientation for TUs. 
 
Figure 3.1 Agarose gel (1% w/v) of Level 0 plasmids, paired lanes of undigested DNA and DNA cut 
with BsaI. L indicates the 1kb Plus DNA Ladder (2-log DNA Ladder) from New England BioLabs. 
The approximate expected band sizes are: for the plant selectable marker (nptII) 2kb and 0.8kb, for 
geranylgeranyl pyrophosphate synthetase (ggs) 2kb and 1kb, for cyclase (cyc) 2.9kb and 2kb, for p450-
1 2kb and 1.5kb, for p450-2 2kb and 1.5kb, for p450-3 2kb and 1.5kb, for short-chain dehydrogenase/ 
reductase (sdr) 2kb and 0.7kb, for acetyltransferase (atf) 2kb and 1.1kb. 
 
3.1.2 Level 1 plasmids 
Having shown the level 0 cDNA plasmids were correct, two approaches were 
followed in order to create L1 (TU; Transcription Unit) plasmids; the first consisting 
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of the same promoter (CaMV 35S) and terminator (nopaline synthase) throughout all 
the TUs and the second using a diversity of transcriptional-regulatory elements, 
shown in Figure 3.3 A & B, and Table 2.8. In each case, the level 0 vector, the donor 
for the promoter region, terminator regions and the L1 acceptor vector were all 
digested with BsaI. Digests were mixed together with ligase and rescued into E. coli 
based on selection of carbenicillin-resistance and white colonies on X-gal (20μg/ml) 
and IPTG (100μM). Plasmid construction was confirmed by restriction digest with 
BpiI to show that the transcriptional unit has been correctly assembled. Indicative 
schematics of Level 0 and Level 1 plasmids are shown in Figure 3.2 (For all Level 0 
and Level 1 plasmid maps see Appendix A). The restriction digest profiles of Level 
1_35S and Level 1_D (Diverse promoters) are depicted in Figures 3.3. 
 
 
Figure 3.2 Plasmids of Level 0 (A) and Level 1 (B) of the ggs gene. All plasmids contain an 
antibiotic resistance gene for E. coli (spectinomycin for Level 0 and carbenicillin for Level 1 plasmid), 
Left and Right Borders for plant transformation via T-DNA transfer. For Level 0 and Level 1 




Figure 3.3 Agarose gel (1% w/v) of Level 1 TU plasmids, paired lanes of undigested DNA and DNA 
cut with BpiI, (A) containing the same promoter (CaMV 35S) and terminator (nopaline synthase) for 
all the TUs and (B) using a diversity of transcription elements for the different TUs. L indicates the 1kb 
Plus DNA Ladder (2-log DNA Ladder) from New England BioLabs, which was used as a marker. The 
approximate expected band sizes are: (A) for nptII 4.4kb and 1.6kb, for ggs 4.4kb and 1.9kb, for cyc 
4.4kb and 3.7kb, for p450-1 4.4kb and 2.4kb, for p450-2 4.4kb and 2.4kb, for p450-3 4.4kb and 2.4kb, 
for sdr 4.4kb and 1.6kb, for atf  4.4kb and 2kb and (B) for nptII 4.4kb and 1.9kb, for ggs 4.4kb and 
2.1kb, for cyc 4.4kb and 4kb, for p450-1 4.4kb and 2.7kb, for p450-2 4.4kb and 2.7kb, for p450-3 
4.4kb and 2.7kb, for sdr 4.4kb and 1.9kb, for atf 4.4kb and 2.3kb. 
 
To confirm that the 35S cassette would work in both M. polymorpha and P. patens, a 






Figure 3.4 Agarose gel (1% w/v) of Level 1 35S::gfp::tnos, paired lanes showing plasmids 
undigested DNA and DNA cut with BpiI. L indicates the 1kb Plus DNA Ladder (2-log DNA Ladder) 
from New England BioLabs, which was used as a marker. The approximate expected band sizes are: 
4.4kb and 1.5kb. 
Transformation of P. patens is more efficient if vectors include a region of 
host DNA, the usual locus being Pp108. Therefore the Pp108 locus was amplified 
from P. patens (see section 2.3.4). As a vector backbone, pICH41331 was used, 
which consists of a Level 0 acceptor (TU vector) for complete gene modules. The 





Figure 3.5 Agarose gel (1% w/v) of Level TU vector and Pp108.1 locus amplicons, where L 
indicates the 1kb Plus DNA Ladder (2-log DNA Ladder) from New England BioLabs, which was used 
as a marker. (A) TU vector loaded cut with BsaI and the approximate expected bands are: 2.2kb and 
0.6kb. (B) PCR amplicons of Pp108.1L and Pp108.1R, with products at 1.1kb and 1.05kb, 
respectively. (C) Level 1 of Pp108.1L and Pp108.1R loaded cut with BpiI and approximate expected 
bands are: for Pp108.1L 4.4kb and 1.1kb, for Pp108.1R 4.4kb and 1.05kb. (D) Cut gel after gel 
extraction in order to ligate the initial Pp108.1 and Pp108.2 loci into the TU vector, with products at 
1.1kb for Pp108.1L and Pp108.2L and 1.05kb for Pp108.1R and Pp108.2R. 
 
3.1.3 Level 2, M and P plasmids 
In order to proceed to Level 2 (multigene constructs), Level 1, Level M for 
position 6 and Level M for position 7 vectors, as well as the end-linker pELB-4 were 
digested using BpiI to confirm they were the correct starting material (Figure 2.6; 
Figure 3.6). 
 
Figure 3.6 Agarose gel (1% w/v) of Level 2, Level M no6, Level M no7 and end-linker pELB4 
vectors, where L indicates the 1kb Plus DNA Ladder (2-log DNA Ladder) from New England 
BioLabs, which was used as a marker. (A) L2 vector loaded uncut and cut with BpiI, with expected 
bands at 8.1kb and 4.2kb and vector pELB-4 loaded uncut and cut with BsaI, with expected bands at 
4.3kb and 0.6kb. (B) LM no6 and LM no7 vectors loaded cut with BpiI, with expected bands at 4.6kb 
and 0.6kb for both vectors. 
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The initial scheme was to make plasmids containing four genes: ggs, cyc, 
p450-1 and nptII. Two versions were planned, one with all genes under control of 35S 
promoter and the other with diverse promoters. The plasmid maps of Level 2.4_D and 
Level 2.4_35S are shown in Figure 3.9. According to the Golden Gate scheme, 
ligation of the first four genes into the L2 vector should have given blue and red 
colonies only, where blue colonies have plasmids which had incorporated the end-
linker and accordingly would be the ones selected for screening. However, apart from 
blue and red colonies, the reaction also led to a high proportion of white colonies. 
These were unexpected and might have been an indication of contamination or 
perhaps were the result of partial/incorrect ligation, thus giving unexpected 
byproducts (Figure 3.7). Therefore in order to eliminate any issues regarding E. coli 
cells or the transformation protocol, transformation efficiency, along with a negative 
control was checked (Figure 3.8).  
 
 
Figure 3.7 Transformation after ligation with Level 2.4 vector, containing the first four genes. 
Blue colonies have the lacZ end-linker, red have received the empty Level 2 vector containing the red 




Two different protocols were conducted, using a heat-shock period of 30 or 50 
seconds, with the rest of the protocol steps staying the same. In the 30sec protocol 130 
colonies were obtained, whereas the 50sec protocol gave 70 colonies (Figure 3.9). As 
a result, transformation efficiency in the first case was 
130cfu
0.05ng
= 2.6 × 106cfu/μgDNA 
and in the second 
70cfu
0.05ng
= 1.4 ×  106cfu/μgDNA, where cfu stands for colony-
forming units. This is a low efficiency of transformation for golden-gate cloning 
methods, which recommends efficiencies of >5x107 cfu/μg DNA. The negative 
control gave no colonies, showing the cells were free of any contamination. Also, the 
E. coli TOP10 competent cells were plated onto LB with spectinomycin, carbenicillin 
or kanamycin, and none of these yielded any colonies, again confirming the cells were 
not contaminated. 
 Lab stocks of E. coli DH5α were also tested to see if they might perform 
better. On plating onto LB, the morphology of the colonies was unexpected 
(spreading and slimy). In addition transformation with the control plasmid pUC19 
gave satellite colonies, which indicates that the cells may not be transformed but are 
resistant to ampicillin through secreted β-lactamase. The stock of DH5α was disposed 




Figure 3.8 E. coli strains DH5α and TOP10, streaked on LB agar plates. (A) DH5α streaked on LB 
agar without antibiotics (B) DH5α transformed with pUC19 plasmid on LB agar with ampicillin (C) 
TOP10 streaked on LB agar without antibiotics (D) TOP10 transformed with pUC19 and 30sec heat-
shock (up-left), 50sec heat-shock (up-right) and a negative control (bottom). 
 
Unfortunately after screening some of the blue colonies, via plasmid 
extraction and restriction digestion, the wrong digest profiles were obtained, 
demonstrating that the lacZ cassette was incorporated but not all of the first four 




Figure 3.9 Predicted Plasmid maps of Level 2.4_D (A) and Level 2.4_35S (B). 
 
Figure 3.10 Agarose gel (1% w/v) of potential Level 2.4_D and Level 2.4_35S plasmids, uncut 
and/or cut with various restriction enzymes. L indicates the 1kb Plus DNA Ladder (2-log DNA Ladder) 
as a marker. Expected bands are shown using asterisks. (A) pL2.4_D clones 1-8 cut with KpnI, with 
expected bands approximately at 11.9kb and 3.7kb (B) pL2.4_D clone 9 and 10, where each first line is 
loaded with uncut plasmid following cut with HindIII, MscI, PvuII and ScaI, respectively, where 
expected bands are at 6.5kb, 4.7kb, 3kb, 1.2kb for HindIII, 9kb, 3.8kb, 2,2kb, 0.5kb for MscI, 7.6kb, 
5kb, 2.6kb, 0.3kb for PvuII, 9kb, 3.5kb, 3kb, 0.2kb for ScaI (C) pL2.4_35S clones 1-8 uncut and cut 
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with HindIII, with expected bands at 6.3kb, 4kb, 2.9kb, 1.2kb (D) pL2.4_35S clones 1-16 cut with 
KpnI and NcoI with expected bands at 8.8kb, 2.6kb, 2.1kb, 0.6kb, 0.3kb. 
 The Level 1 plasmids which deliver each cassette had not previously been 
digested with these enzymes so there was a possibility that the predicted maps were 
incorrect, therefore the first four Level 1 transcription units were digested with 
HindIII and/or MscI. This did give the expected profile (Figure 3.11), showing that 
the predicted maps were accurate and what had been obtained from the ligation was 
incorrect. Consequently, the troubleshooting was then focused on the dig-lig reaction 
conditions, contents and proportions. After testing multiple protocols, the final 
protocol that seemed to work best consisted of a double cycle number (50 cycles 
instead of 26), the addition of the 10x Buffer G, containing 0.1 mg/ml BSA, provided 
by Thermo and the T4 ligase, also provided by Thermo instead of the T4 ligase by 
New England Biolabs which was initially used (see section 2.3.3). This approach led 
to an increased number of colonies, eliminating colonies with the wrong colour and 
after screening nearly all chosen colonies depicted the correct digestion profile. 
 
Figure 3.11 Agarose gel (1% w/v) of Level 1 and plasmids for the first four genes, cut with 
various restriction enzymes. L indicates the 1kb Plus DNA Ladder (2-log DNA Ladder) from New 
England BioLabs, which was used as a marker. 1st lane: pL1_pact2::ggs::t35S cut with HindIII and 
MscI with expected bands at 5.3kb, 0.4kb, 3rd lane: pL1_pmas::cyc::tosc cut with HindIII with 
expected bands at 6.8kb, 1.2kb, 4th lane: pL1_p35S2x::nptII::tnos cut with MscI with expected bands at 
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4.5kb, 1kb, 0.4kb, 5th lane: pL1_pact2::p450-1::t35S cut with MscI with expected bands at 4.7kb, 
1.6kb, 0.4kb. 
After altering the dig-lig reaction protocol, the correct digest profiles were 
obtained (Figure 3.12, for plasmid maps see Appendix A). The separate dig-lig 
reactions were set as shown in Figure 2.6 and blue/white selection determined the 
isolation of the correct colour from each reaction/ plate. From this stage only the same 
35S promoter approach continued. The pL2.3 plasmid, containing the genes nptII, ggs 
and cyc was isolated from white colonies, the pL2.4 plasmid containing the genes 
nptII, ggs, cyc and p450-1 was isolated from blue colonies and the pL2.6 plasmid, 
containing the genes nptII, ggs, cyc, p450-1, p450-2, and sdr was also isolated from 
blue colonies. 
Figure 3.12 Agarose gel (1% w/v) of Level 2.3, 2.4 and 2.6 plasmids, cut with various restriction 
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enzymes. L indicates the 1kb Plus DNA Ladder (2-log DNA Ladder) from New England BioLabs, 
which was used as a marker. (A) pL2.3, containing the genes ggs, cyc, nptII uncut (lanes1,2) and cut with 
BamHI (lanes 4, 5) with expected bands at 7kb, 2.6kb, 1.2kb, 0.6kb or HindIII (lanes 7, 8) with expected 
bands at 9.2kb, 1.2kb, 1kb, (B) pL2.4, containing the genes ggs, cyc, nptII, p450-1 uncut (lanes 1-5) and 
cut with HindIII (lane 6-10) with expected bands at 6.5kb, 5.6kb, 1.2kb, 1kb, NcoI (lanes 12-16) with 
expected bands at 9.8kb, 4kb, 0.6kb or BsaI (lane 18) with expected bands at 13.8kb, 0.6kb, (C) pL2.6, 
containing the genes ggs, cyc, nptII, p450-1, p450-2, sdr cut with HindIII throughout the gel with 
expected bands at 9.6kb, 6.5kb, 1.2kb, 1kb, (D) pL2.6, containing the genes nptII, ggs, cyc, p450-1, 
p450-2, sdr cut with KpnI throughout the gel with expected bands at 9.8kb, 6.1kb, 2.1kb, 0.3kb. Clone 1, 
for pL2.3 and pL2.4, and clone 22 (red box) for pL2.6 were used in further experiments. 
 
The first plasmid that was used for establishing Agrobacterium-mediated 
transformation of M. polymorpha within the lab was the one indicated as pL2.6 clone 
22, shown in the red box in Figure 3.12. Despite repeated attempts with the 
transformation protocol for M. polymorpha, only necrotic thalli were generated with 
no successful geneticin-resistant lines. Careful scrutiny of the initial Level 0 coding 
sequence of the nptII gene (made by previous workers in the lab) led to the realization 
that its anti-sense form was cloned, thus resulting in a dysfunctional transcription unit. 
This assumption was also confirmed by sequencing. The correct orientation was 
therefore cloned into the Level 0 acceptor vector, pICH41308, amplified from the 
plasmid pICSL70004, using specific primers (see section 2.3.4; Figure 3.13). Level 0 
plasmid was used to clone nptII into a Level 1 vector containing the 35S promoter and 
nopaline synthase terminator, and then used to make new Level 2 plasmids as detailed 
in Figure 3.14. When these correct constructs were used in transformation of M. 




Figure 3.13 Agarose gel (1% w/v) of pICH41308, pICSL70004, nptII amplicon, Level 0 and Level 
1, and initial Level 1 nptII. L indicates the 1kb Plus DNA Ladder. (A) pICSL70004 that contains the 
nptII coding sequence cut with BsaI and NcoI, with expected bands at 2.2kb, 1.5kb, 0.4kb, (B) 
pICH41308 loaded uncut and cut with BsaI, with expected bands at 2.2kb, 0.6kb, (C) PCR product of 
nptII with special flanking sites at 0.8kb and gel extraction, (D) pL0_nptII cut with BsaI with expected 
bands at 2.2kb, 0.8kb, (E) pL1_35S::nptII::tnos cut with BpiI with expected bands at 4.3kb, 1.6kb, (F) 






Figure 3.14 Agarose gel (1% w/v) of pL2.2, pL2.5 and pL2.7, all units containing the 35S 
promoter. L indicates the 1kb Plus DNA Ladder. (A) pL2.2_ggs::cyc::nptII::ELB3 map, (B) pL2.2, 
containing the genes ggs, cyc, nptII cut with BamHI (lanes 2, 3) with expected bands at 4.6kb, 2.9kb, 
2.6kb, 1.2kb, 0.6kb (green arrows) or HindIII (lanes 4, 5) with expected bands at 6.5kb, 3.2kb, 1.2kb, 
1kb (orange arrows), (C) pL2.5_ggs::cyc::nptII::p1::p2::sdr::ELB6 map, (D) pL2.5, containing the 
genes ggs, cyc, nptII, p450-1, p450-2, sdr cut with HindIII (lanes 2, 3) with expected bands at 9.5kb, 
6.5kb, 1.2kb, 1kb (orange arrows), BsaI (lanes 2-7) with expected bands at 17.7kb, 0.6kb (green 
arrows), or PstI (lanes 9-13) with expected bands at 10.9kb, 5.4kb, 1.5kb, 0.6kb (blue arrows), (E) 
pL2.7_ggs::cyc::nptII::p1::p2::sdr::atf::p3::ELE1 map, (F) pL2.7, containing the genes ggs, cyc, nptII, 
p450-1, p450-2, sdr, atf, p450-3 cut with KpnI (lanes 2,4) with expected bands at 15.7kb, 6.1kb, 0.3kb 
(green arrows) or HindIII (lanes 3,5) with expected bands at 10.8kb, 7.6kb, 1.4kb, 1.2kb, 1kb (orange 
arrows). 
 
Table 3.1 Final plasmids made and used in transformation of M. polymorpha and Agro-
infiltration of tobacco. 
 
pL1Empty pL2.2 pL2.5 pL2.7 




nptII nptII, ggs, cyc 
nptII, ggs, cyc, 
p450-1, p450-2, sdr 
nptII, ggs, cyc, p450-1, 







Chapter 4: Assessing host-plant sensitivity to mutilins 




This chapter describes a series of investigations to determine whether the 
target plant hosts were susceptible to mutilin antibiotics. If they were sensitive, this 
might limit the utility as hosts for heterologous expression. To achieve this, the moss 
P. patens and liverwort M. polymorpha were grown in media as described in section 
2.2.2, supplemented with a dilution series of antibiotics that cover a wide range of 
mechanisms of action, including pleuromutilin derivative, tiamulin, and mutilin, such 
as the pleuromutilin derivative, tiamulin, and a precursor of pleuromutilin, mutilin. 
Denagard® (tiamulin hydrogen fumarate) was used as a semi-synthetic pleuromutilin 
derivative. In addition, the antibiotics chloramphenicol, kanamycin and nalidixic acid 
were used in both plant growth assays, while ampicillin was also tested in M. 
polymorpha. These additional assays were carried out as positive controls, as there 
has been relevant work in the literature (Kasten & Reski, 1997; Katayama et al., 2003; 
Tounou et al., 2002). Detailed preparation of antibiotics is shown in Table 2.3. All 
antibiotics were supplemented in the media at concentrations of: 0μg/ml (untreated), 
1μg/ml, 5μg/ml, 10μg/ml, 50μg/ml, 100μg/ml, 200μg/ml, 250μg/ml and 500μg/ml. 
Untreated plants were mock treated using solvent as indicated in Sections 2.2.2 and 
2.3.  
4.1.1 Effect of antibiotics on growth of P. patens and M. polymorpha 
The pleuromutilin derivative, tiamulin, appears to affect the growth of both 
plants, causing a reduction in size. P. patens was viable when grown in up to 10μg/ml 
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tiamulin (Figure 4.1), but a reduction in moss colony diameter was observed with 
concentrations higher than1μg/ml. At concentrations higher than 10μg/ml there was 
no growth. M. polymorpha was more tolerant and could generate a thallus when 
grown in up 50μg/ml, although there was a visible effect on thallus growth at 
concentrations above 1 μg/ml tiamulin (Figure 4.2). Complete inhibition of growth 
was observed at concentrations higher than 50mg/ml. 
Mutilin is a pathway precursor of pleuromutilin. When tested with P. patens, 
this still supported a colony diameter of 0.3cm at 250μg/ml. At concentrations higher 
than 250mg/ml, there was no growth.  This means that mutilin needed an approximate 
25-fold increase in antibiotic concentration to deliver the same level of growth 
inhibition when compared to tiamulin. In M. polymorpha, a similar outcome was 
observed, with an average of 0.1cm2 thallus area produced at the highest 
concentration of 500μg/ml mutilin (Figures 4.3 and 4.4), indicating a 10-fold greater 
tolerance to mutilin compared to tiamulin. 
When supplemented with chloramphenicol, moss colony diameter showed a 
moderate decrease in growth, where at 50μg/ml this decrease was readily observed, 
while at concentrations greater than 100μg/ml the inoculum did not grow. In contrast, 
Marchantia thalli were not notably affected at low concentrations, yet showed a 
dramatic reduction in growth at 50μg/ml, indicating a tolerance threshold. At higher 
concentrations gemmae did not generate thalli (Figures 4.5 and 4.6).   
The treatment of P. patens with kanamycin had little effect at concentrations 
up to 10μg/ml, but there was a considerable decrease in colony diameter between 50 
and 100μg/ml and no growth at higher concentrations. In M. polymorpha a similar 
result was observed, with little effect of kanamycin at low concentrations, but a sharp 
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decline in thallus area above 50μg/ml. There were some occasions where growth of 
thalli up to 250μg/ml was observed (Figures 4.7 and 4.8). 
 
Figure 4.1 Tiamulin treatment assay for P. patens (left) and M. polymorpha (right), grown on 
tiamulin concentrations ranging from 1 to 500μg/ml. Mock assays were treated using solvent 
(untreated). Each assay consisted of 3 technical replicates (representative images shown above with 
additional replicates in Appendix B, for P. patens n=15 and for M. polymorpha n=15). Scale bar is at 
25mm. 
 
Figure 4.2 Tiamulin treatment assay for P. patens (A) and M. polymorpha (B), grown on tiamulin 
concentrations ranging from 1 to 500μg/ml. Mock assays were treated using solvent (untreated). Values 














































polymorpha (B), respectively. Each assay consisted of 3 technical replicates, measured according to 
Figure 3.15 and the other replicates (shown in Appendix B, for P. patens n=15 and for M. polymorpha 
n=15). 
 
Figure 4.3 Mutilin treatment assay for P. patens (left) and M. polymorpha (right), grown on 
mutilin concentrations ranging from 1 to 500μg/ml. Mock assays were treated using solvent 
(untreated). Each assay consisted of 3 technical replicates (representative images shown above with 
additional replicates in Appendix B, for P. patens n=10 and for M. polymorpha n=15). Scale bar is at 
25mm. 
 
Figure 4.4 Mutilin treatment assay for P. patens (A) and M. polymorpha (B), grown on mutilin 















































are the average ±SD measurements of colony diameter of P. patens (A) and thallus area of M. 
polymorpha (B), respectively. Each assay consisted of 3 technical replicates, measured according to 
Figure 3.17 and the other replicates (shown in Appendix B, for P. patens n=10 and for M. polymorpha 
n=15). 
 
Figure 4.5 Chloramphenicol treatment assay for P. patens (left) and M. polymorpha (right), grown 
on media containing chloramphenicol concentrations ranging from 1 to 500μg/ml. Mock assays were 
treated using solvent (untreated). Each assay consisted of 3 technical replicates (representative images 
shown above with additional replicates in Appendix B, for P. patens n=15 and for M. polymorpha 












































Figure 4.6 Chloramphenicol treatment assay for P. patens (A) and M. polymorpha (B), grown on 
chloramphenicol concentrations ranging from 1 to 500μg/ml. Mock assays were treated using solvent 
(untreated). Values are the average ±SD measurements of colony diameter of P. patens (A) and thallus 
area of M. polymorpha (B), respectively. Each assay consisted of 3 technical replicates, measured 
according to Figure 3.19 and the other replicates (shown in Appendix B, for P. patens n=15 and for M. 
polymorpha n=10). 
 
Figure 4.7 Kanamycin treatment assay for P. patens (left) and M. polymorpha (right), grown on 
kanamycin concentrations ranging from 1 to 500μg/ml. Mock assays were treated using solvent 
(untreated). Each assay consisted of 3 technical replicates (representative images shown above with 





Figure 4.8 Kanamycin treatment assay for P. patens (A) and M. polymorpha (B), grown on 
kanamycin concentrations ranging from 1 to 500μg/ml. Mock assays were treated using solvent 
(untreated). Values are the average ±SD measurements of colony diameter of P. patens (A) and thallus 
area of M. polymorpha (B), respectively. Each assay consisted of 3 technical replicates, measured 
according to Figure 3.21 and the other replicates (shown in Appendix B, for P. patens n=15 and for M. 
polymorpha n=15). 
 
Treatment of moss with nalidixic acid gave a decline in growth starting from 
the treatment of 1μg/ml, while at concentrations higher than 10μg/ml there was total 
inhibition of growth. It is worth mentioning that a considerable decrease in size was 
observed in untreated samples. Additionally, when supplemented in M. polymorpha 
media, nalidixic acid repressed growth at concentrations above 5μg/ml, with only rare 
instances of thalli growth at 5μg/ml (Figures 4.9 and 4.10). 
As far as the treatment with ampicillin is concerned, M. polymorpha thalli 
only showed a small reduction in growth at concentrations over 100μg/ml (Figures 

















































Figure 4.9 Nalidixic acid treatment assay for P. patens (left) and M. polymorpha (right), grown on 
nalidixic acid concentrations ranging from 1 to 500μg/ml. Mock assays were treated using solvent 
(untreated). Each assay consisted of 3 technical replicates (representative images shown above with 
additional replicates in Appendix B, for P. patens n=15 and for M. polymorpha n=15). Scale bar is at 
25mm. 
 
Figure 4.10 Nalidixic acid treatment assay for P. patens (A) and M. polymorpha (B), grown on 
nalidixic acid concentrations ranging from 1 to 500μg/ml. Mock assays were treated using solvent 
(untreated). Values are the average ±SD measurements of colony diameter of P. patens (A) and thallus 














































according to Figure 3.23 and the other replicates (shown in Appendix B, for P. patens n=15 and for M. 
polymorpha n=15). 
 
Figure 4.11 Ampicillin treatment assay for M. polymorpha, grown on ampicillin concentrations 
ranging from 1 to 500μg/ml. Mock assays were treated using solvent (untreated). The assay consisted 
of 3 technical replicates (representative images shown above with additional replicates in Appendix B,  
for M. polymorpha n=15). Scale bar is at 25mm. 
 
Figure 4.12 Ampicillin treatment assay for M. polymorpha, grown on ampicillin concentrations 
ranging from 1 to 500μg/ml. Mock assays were treated using solvent (untreated). Values are the 





















replicates, measured according to Figure 3.25 and the other replicates (shown in Appendix B, for M. 
polymorpha n=15). 
 
4.1.2 Effect of antibiotics on the morphology of P. patens and M. polymorpha 
 Treatment using different antibiotics led to the appearance of different 
characteristic phenotypes. Untreated moss had a colony morphology consisting of 
filaments and covered with leafy gametophores as shown in Figure 4.13. Treatment 
with mutilin at a concentration above 50μg/ml led to compact colonies with 
filamentous protonemata and reduced number of leafy gametophores (Fig 4.13 B) or 
solely filamentous protonemata at concentrations higher than 100μg/ml (Fig 4.13 C). 
This latter morphology was also observed with chloramphenicol treatment at the 
concentration of 50μg/ml and kanamycin treatment at the concentration of 100μg/ml. 
 
Figure 4.13 Developmental effects of antibiotics on P. patens. (A) Untreated colonies grown in 
solvent, (B) mutilin at 50μg/ml and (C) mutilin at 100μg/ml or above. Similar effects were seen in 
plants gnown on media containing chloramphenicol at 50μg/ml or above, or kanamycin at 100μg/ml or 
above. Scale bar is at 10mm. 
 
Untreated M. polymorpha thalli demonstrate a dorsiventral pattern with 
gemma cups, where gemmae are produced as shown in Figure 4.14. When plants were 
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grown on concentrations equal or higher than: 10μg/ml pleuromutilin, 100μg/ml 
mutilin, 100μg/ml kanamycin and 1μg/ml nalidixic acid, the “intermediate 
phenotype” was produced with a hyponastic curvature of the thallus, a reduced size 
and reduced dorsiventrality, but still producing rhizoids (Fig 4.14 B). Gemma cups 
are non-existent in this figure, but thalli eventually are capable of developing a few 
gemma cups, days or weeks later than untreated cultures. Treatments with kanamycin 
above 100μg/ml gave a severe impact on morphology which appeared as an 
undifferentiated mass, (Fig 4.14 C). 
 
Figure 4.14 Developmental effects of antibiotics on M. polymorpha. (A) Untreated colonies grown 
in solvent, (B) pleuromutilin, mutilin, kanamycin or nalidixic acid and (C) kanamycin. Scale bar is at 
10mm. 
Along with the macro-morphology of moss colonies, filamentous protonemata 
were observed under the microscope in order to evaluate the impact of the antibiotics 
on chloroplast numbers and locations. Pleuromutilin (5μg/ml) and mutilin (100μg/ml) 
had no obvious impact on either protonemata morphology or chloroplasts as shown in 
Figure 4.15, apart from reduction of protonemata perimeter observed in Figure 4.1 
and 4.3, respectively. In contrast, chloramphenicol (100μg/ml), kanamycin 
(100μg/ml) and nalidixic acid (10μg/ml) led to a degraded appearance of protonemata 




Figure 4.15 Effects of antibiotics on P. patens protonemata. (A) Untreated colonies grown in 
solvent, (B) pleuromutilin (5μg/ml), (C) mutilin (100μg/ml), (D) chloramphenicol (100μg/ml), (E) 
kanamycin (100μg/ml) and (F) nalidixic acid (10μg/ml). Scale bar is at 100μm. 
 The sensitivity of M. polymorpha and P. patens appeared to be sufficiently 
low for mutilin but relatively high for the pleuromutilin derivative, tiamulin. 
However, without having fine-tuned the heterologous expression in planta, it was 
possible that the hosts would be producing quite low concentrations of the 





Chapter 5: Heterologous plant hosts for expression of 
the pleuromutilin biosynthetic pathway 
 
5.1 Aim 
The aim of this chapter was to obtain M. polymorpha transformants, analyse 
gene expression and detect metabolites. The pleuromutilin derivative, tiamulin, 
caused a reduction in size of P. patens colonies diameter at 10μg/ml tiamulin (Figure 
4.1), with a smaller reduction at 1μg/ml, and no growth at concentrations higher than 
10μg/ml. M. polymorpha was more tolerant and could generate a thallus when grown 
in up to 50μg/ml, although growth was affected in concentration of 1μg/ml tiamulin 
(Figure 4.2), while total inhibition of growth was observed at concentrations higher 
than 50mg/ml. Due to these observations, the 2-gene and 5-gene construct were used 
in order to study three critical steps in pleuromutilin pathway, the cyclization of 
GGPP to 3-deoxo-11-dehydroxy-mutilin (2-gene construct) and the dehydrogenation 
of 3,11-dihydroxy premutilin to mutilin (5-gene construct) and the hydroxylation of 
14-O-acetylmutilin to pleuromutilin. 
5.1.1 Agrobacterium-infiltration of tobacco led to chlorotic leaves 
 Leaves of approximately 5-week-old tobacco were infiltrated with the empty 
vector, the 2-gene vector, the 5-gene vector or the 7-gene vector in the underside of 
the third leaf from the shoot apical meristem leaving a dark-green area (‘’wetting’’ 
area). The leaves were observed and harvested 3, 5 and 7 days post-infection (d.p.i.). 
The tobacco leaves shown in Figure 5.1 demonstrate a characteristic chlorotic tint, 
which became more visible at later days. This was more severe in the expression 
vectors where there was typically severe necrosis observed in the infiltrated regions, 
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particularly with vectors 2.5 and 2.7. Tissue was ground into a fine powder, which 
was used for metabolite extraction and HPLC analysis. 
 
Figure 5.1 Tobacco leaves Agrobacterium-infiltration with the different plasmids, 3, 5 and 7 days 
post-infection. Untreated or WT leaves (1st row), empty vector leaves that were infiltrated using an 
empty vector (2nd row), leaves infiltrated using Agrobacteria transformed with the 2-gene construct (3rd 






5.1.2 HPLC analysis of extracts from infiltrated leaves 
 In an attempt to search for pleuromutilin and pleuromutilin precursor 
production, extracts from infiltrated tobacco leaves were analyzed through HPLC. 
The leaves were harvested 3, 5 and 7 days post-infection and as control sample the 
empty vector leaves were used. Three different leaves were harvested for each 
timepoint and vector and independently assessed as technical replicates. Overall, 3 
individual leaves-samples per d.p.i. were analyzed, derived from 4 categories of 
infiltrated leaves with: an empty vector, the 2-gene, 5-gene and 7-gene construct 
detailed in Section 2.4.4.  
Representative samples are shown in HPLC chromatograms in Figure 3.34. 
Despite careful analysis there were no apparent peaks with the same retention as the 
previously purified and characterized mutilin for the 5-gene construct or pleuromutilin 
for the 7-gene constructs at retention time (Rt) 12.24 at with mass 366 in the ES- 
spectrum and at Rt 11.97 at with mass 423 in the ES- spectrum, respectively. As a 
pleuromutilin indicator (positive control), pleuromutilin (≥95% purity) from Sigma-
Aldrich was used. Furthermore, the 2-gene construct hypothetically leading to the 
production of the first cyclised compound, 3-deoxy-11-dehydroxy-mutilin, was 
expected to be observed with the mass 289 in the ES- spectrum and no such signal 




Figure 5.2 HPLC analysis of tobacco leaf extracts; extracted ion chromatographs for 289 (A, B), 
366 (C, D) and 423 (E, F, G) in the ES- spectrum. (A) Extract from tobacco leaves infiltrated with 
Agrobacteria harbouring an empty vector for 289 in the ES- spectrum. (B) Extract from tobacco leaves 
infiltrated with Agrobacteria harbouring the 2-gene construct for 289 in the ES- spectrum. (C) Extract 
from tobacco leaves infiltrated with Agrobacteria harbouring an empty vector for 366 in the ES- 
spectrum. (D) Extract from tobacco leaves infiltrated with Agrobacteria harbouring the 5-gene vector 
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for 366 in the ES- spectrum. Rt should be observed at 12.24 (red dashed line) (E) Extract from tobacco 
leaves infiltrated with Agrobacteria harbouring an empty vector for 423 in the ES- spectrum. (F) 
Extract from tobacco leaves infiltrated with Agrobacteria harbouring the 7-gene vector for 423 in the 
ES- spectrum. Rt should be observed at 11.97 as shown in positive control.  (G) Positive control of 
pleuromutilin ≥95% for 423 in the ES- spectrum. 
 
5.2.1 Marchantia transformation using cut thalli  
In order to observe in detail the growth of the wild-type Tak-1 line, the 
development of gemmalings was observed for 14 days (Figure 5.3). Transformation 
protocols recommend thalli of 8-12mm, therefore transformation of M. polymorpha 
was conducted using 14-day old cut thalli. All transformations were performed using 
co-cultivation with Agrobacterium LBA4404, harboring the construct under study 
each time.  
 
Figure 5.3 Time-course observation of Tak-1 WT thalli. 14-day old thalli were used in the 
transformation protocol described at Section 2.8. Black scale bar (Day 0) is at 0.5mm. White scale bar 
(Day 3-14) is at 2mm. 
The 14-day old thalli were cut in four fragments each and left to recover under 
normal conditions for 7 days prior to transformation (Figure 5.4, A). These typically 
were able to reform the characteristic apical notches (Figure 5.4, A). After co-
cultivation for 3 days with Agrobacteria containing the construct under study, 
plantlets were transferred onto half strength Gamborg’s B5 medium supplemented 
with 1% (w/v) sucrose, cefotaxime and Geneticin® (Figure 5.4, B). Geneticin-
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resistant thalli were apparent 15 days after transfer to the above selective media, while 
the original cut thalli became necrotic (Figure 5.4, D; Figure 5.5, C). Isogenic lines 
were obtained after 2 cycles of transplantation of gemmae (G2 generation), which 
were used for further analyses. 
 
Figure 5.4 Marchantia transformation protocol workflow. (A) Cut thalli on half strength Gamborg’s 
B5 supplemented with 1% (w/v) sucrose. (B) After 3 days of co-cultivation with Agrobacteria, the thalli 
were transferred into half strength Gamborg’s B5 medium supplemented with 1% (w/v) sucrose, 
cefotaxime and geneticin® (selection media) (C) Necrotic thallus that derived from Agrobacterium-
mediated transformation, harbouring a plasmid that contained a non-functional selection marker gene 
nptII. (D) Two weeks after transfer to selective media geneticin-resistant thalli were observed. For those 
transformed with a functional nptII.  Scale bar is at 10mm. 
 
Figure 5.5 Characteristic morphology of Marchantia thalli during transformation. (A) 7-day healthy 
thallus growing under normal conditions after being cut and prior to transformation (see Section 2.8). (B) 
Necrotic thallus that derived from untransformed or negative control/ failed transformants on exposure to 
geneticin. (C) Geneticin-resistant thalli were observed 15 days after transfer to the selective media 




 It is worth mentioning that the plantlets transformed with the initial plasmids, 
(harbouring the anti-sense and therefore non-functional nptII selection gene) did not 
lead to regenerated thalli, indicating that were not any geneticin-resistant thalli 
(Figure 5.4, C; Figure 5.5, B). 
 
Table 5.1 Different groups/ lines of Marchantia transformed with individual constructs detailed 
in Section 2.4.4. All transcription units had the 35S promoter and nos terminator. 
 
Group E Group A Group B Group C 




nptII nptII, ggs, cyc 
nptII, ggs, cyc, 
p450-1, p450-2, sdr 
nptII, ggs, cyc, p450-1, 
p450-2, sdr, atf, p450-3 
 
 
5.2.2 HPLC analysis of Marchantia tissue   
Extracts from Marchantia tissue were analyzed through HPLC for any trace of 
pleuromutilin or pleuromutilin precursors. The control sample was Marchantia 
transformed with an empty vector. Overall, 8 individual samples per vector were 
analyzed, derived from 4 categories of transformed Marchantia with: an empty 
vector, the 2-gene, 5-gene and 7-gene construct detailed in Section 2.4.4. 
Representative samples are shown in HPLC graphs in Figure 5.6, where the 
peaks with the same retention as the previously purified and characterized mutilin for 
the 5-gene construct and pleuromutilin for the 7-gene constructs, with peaks expected 
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in HPLC at retention time (Rt) 12.24 at mass 366 in the ES- spectrum and at Rt 11.97 
at mass 423 in the ES- spectrum, respectively. As a pleuromutilin indicator (positive 
control), pleuromutilin ≥95% from Sigma-Aldrich was used. Furthermore, the 2-gene 
construct hypothetically leading to the production of the first cyclised compound, 3-
deoxy-11-dehydroxy-mutilin, was expected to be observed for the mass 289 in the 
ES- spectrum. The peak at retention time (Rt) 12.24 with mass 366 in the ES- 
spectrum was observed in two different samples, indicating the possibility of 
heterologous production of the precursor mutilin. Those samples belong to the 3rd 
group (group B), transformed with the 5-gene construct leading to the production of 





Figure 5.6 HPLC analysis of M. polymorpha tissue extracts for 289 (A, B), 366 (C, D) and 423 (E, 
F, G, H) in the ES- spectrum. (A) Extract from M. polymorpha harbouring an empty vector T-DNA 
for 289 in the ES- spectrum. (B) Extract from M. polymorpha harbouring the 2-gene construct T-DNA 
for 289 in the ES- spectrum. (C) Extract from M. polymorpha harbouring an empty vector T-DNA for 
366 in the ES- spectrum. (D) Extract from M. polymorpha B4 harbouring the 5-gene T-DNA for 366 in 
the ES- spectrum. Rt should be observed at 12.24. (E) A second sample extract from M. polymorpha 
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B3 harbouring harbouring the 5-gene T-DNA for 366 in the ES- spectrum. Rt should be observed at 
12.24. (F) Extract from M. polymorpha harbouring an empty vector T-DNA for 423 in the ES- 
spectrum. (G)  Extract from M. polymorpha harbouring the 7-gene construct vector T-DNA for 423 in 
the ES- spectrum. Rt should be observed at 11.97 as shown in positive control. (H) Positive control of 
pleuromutilin ≥95% for 423 in the ES- spectrum.  
 
5.2.3 Expression analysis of the genes under study in M. polymorpha 
 In order to examine the expression levels of each gene of the biosynthetic 
pathway of pleuromutilin, tissue from Marchantia transformants was ground into a 
fine powder and total RNA was isolated. Successful RNA isolation was confirmed by 
gel electrophoresis showing the presence of 28S, 18S and 5S ribosomal RNA (rRNA 
(Figure 5.7). Residual genomic DNA removal was conducted for each sample and the 
protocol for Luna® Universal one-step RT-qPCR was followed, with each sample 
being run in triplicate (n=3). 
 
Figure 5.7 0.8% agarose gel of RNA samples after total RNA purification and genomic DNA 
removal from Marchantia polymorpha. Successful isolation of RNA is indicated by the observation 
of the 3 distinctive bands at 3kb, 2kb and 120bp, representing 28S, 18S and 5S ribosomal RNA 
(rRNA), respectively. 
Expression levels of the different genes in Marchantia were evaluated by the 
relative quantification of the respective mRNA transcripts using specific primers. The 
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expression levels from the endogenous house-keeping gene actin7 were used as the 
reference for normalization of qPCR data. Actin7 transcription levels are reported to 
be constant during diverse biological states such as abiotic stress, hormone treatment 
and different developmental stages (Saint-Marcoux et al., 2015). 
Whilst Agrobacterium-mediated transformation tends to result in single-copy 
insertion of constructs in Marchantia, the site of insertion will vary and so some lines 
may have inserts in chromatin regions that are poorly expressed compared to other 
lines. qPCR was performed to determine the plant lines in which the genes are 
incorporated into transcriptionally active regions, resulting in heterologous 
expression. In the following figures, expression levels of each gene in transformant 
groups A, B and/or C are shown compared to the expression levels of the empty 
vector group E that was used as a control. As expected, in control lines or empty 
vector lines, no heterologous expression of the genes was apparent.  
For group A (2-gene, GGS and cyclase transformants) GGPP synthase gene 
heterologous expression was readily evident in lines A2 and A8, with the lines A6 and 
A7 showing low expression (Figure 5.8). Terpene cyclase gene illustrates a similar 
expression pattern with clear heterologous expression in lines A2 and A8 (Figure 5.9).  
In group B (5-gene transformants; GGS, cyclase, P450-1, P450-2 , SDR), lines 
B3 and B6 has obvious expression for GGPP synthase with weak expression in B4 
and B5 (Figure 5.8). The terpene cyclase showed a similar pattern with strong 
expression for lines B3 and B6, but weak expression only for B4 (Figure 5.9).  
In group C, line C7 had good expression for both and (Figures 5.8 & 5.9). 





Figure 5.8 qPCR data analysis of the GGPP synthase gene in control (transformed with an empty 
vector) and transformed with the gene under study (ggs) lines of M. polymorpha. A1-A8 samples 
were transformed with the 2-gene plasmid, B1-B8 samples were transformed with the 5-gene plasmid 
and C1-C8 samples were transformed with the 7-gene plasmid. Asterisks indicate 3 different groups of 
heterologous expression, (*): low/medium expression, (**): medium/high expression, (***): highest 
expression group. In each sample, values depict the mean ±SD where n=3. 
 
Figure 5.9 qPCR data analysis of the terpene cyclase gene in control (transformed with an empty 
vector) and transformed with the gene under study (cyc) lines of M. polymorpha. A1-A8 samples 
were transformed with the 2-gene plasmid, B1-B8 samples were transformed with the 5-gene plasmid 
and C1-C8 samples were transformed with the 7-gene plasmid. Asterisks indicate 2 different groups of 
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heterologous expression, (*): low/medium expression, (**): highest expression group. In each sample, 
values depict the mean ±SD where n=3. 
 As far as the relative expression of the cytochrome p450-1 is concerned, B8 had high 
expression levels, B1, B7, demonstrated weak heterologous expression of p450-1 gene, while 
B2-B6 gave no apparent signal (Figure 5.10). Heterologous expression of P450-1 was also 
observed in lines with the 7-gene construct, strongly in C5, and weakly in C1, C2, C4, C6 
(Figure 5.10). 
 
Figure 5.10 qPCR data analysis of the cytochrome p450-1 gene in control (transformed with an 
empty vector) and transformed with the gene under study (p450-1) lines of M. polymorpha. B1-B8 
samples were transformed with the 5-gene plasmid and C1-C8 samples were transformed with the 7-
gene plasmid. Asterisks indicate 2 different groups of heterologous expression, (*): low/medium 
expression, (**): highest expression group. In each sample, values depict the mean ±SD where n=3. 
 The gene p450-2 is also expressed in lines B3, B4, B6 (Figure 5.11) and C4, C5, C6, 




Figure 5.11 qPCR data analysis of the cytochrome p450-2 gene in control (transformed with an 
empty vector) and transformed with the gene under study (p450-2) lines of M. polymorpha. B1-B8 
samples were transformed with the 5-gene plasmid and C1-C8 samples were transformed with the 7-
gene plasmid. Asterisks indicate 3 different groups of heterologous expression, (*): low/medium 
expression, (**): medium/high expression, (***): highest expression group. In each sample, values 
depict the mean ±SD where n=3. 
Short-chain reductase mRNA levels were noticeable in samples B3, B4, B6, while in 
the group C samples all lines C1-C7, apart from C8, show relative expression compared to the 
empty vector control samples (Figure 5.12).  
 
Figure 5.12 qPCR data analysis of the short-chain reductase gene in control (transformed with an 
empty vector) and transformed with the gene under study (sdr) lines of M. polymorpha. B1-B8 
samples were transformed with the 5-gene plasmid and C1-C8 samples were transformed with the 7-
gene plasmid. Asterisks indicate 3 different groups of heterologous expression, (*): low/medium 
expression, (**): medium/high expression (or highest for the left graph), (***): highest expression 
group. In each sample, values depict the mean ±SD where n=3. 
 
In the group C of the 7-gene construct transformants, acetyltransferase expression is 
apparent in lines C1, C5, C6 and C7 (Figure 5.13, left graph). The final gene of the 
138 
 
pleuromutilin 7-gene construct, p450-3, is heterologously expressed in samples C3, C5, C6, 
C7 and C8 (Figure 5.13, right graph).  
However, it is clear that there are differences in fold expression between some 
individual genes or between different groups of the same gene. It was also noticeable that 
some lines were expressing some of the genes even though no expression was detected for 
some other genes of the same line/construct. This was expected as the Ct where signal was 
observed for the reference gene was at around 18-20 cycles, for Group B genes at around 24-
26 cycles, while for Group A and C at around 29-31 cycles. 
 
Figure 5.13 qPCR data analysis of the acetyltransferase (left) and cytochrome p450-3 (right) 
genes in control (transformed with an empty vector) and transformed with the genes under study 
(atf or p450-3) lines of M. polymorpha. C1-C8 samples were transformed with the 7-gene plasmid. 
Asterisks indicate 3 different groups of heterologous expression, (*): low/medium expression, (**): 
medium/high expression (or highest for the left graph), (***): highest expression group. In each 
sample, values depict the mean ±SD where n=3. 
 According to the aforementioned, it is essential to screen more plant lines to 
acquire sufficient overexpression of the cluster, since the lines analysed did not highly 
express all genes at the same time. Further optimization of gene expression is needed 
to result in lines expressing all seven genes of the pathway. The relative expression is 




Figure 5.14 Summary illustration of the pleuromutilin gene cluster with every M. polymorpha line and their 
respective gene expression levels.  
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Chapter 6: Discussion and Further work 
 Until very recently the pleuromutilins were regarded as a niche class of 
antibiotic with few practical uses in medicine due to lack of oral availability, or 
toxicity issues, however this has changed with the discovery of Lefamulin. With this 
being usable in both tablet and IV injection, this version has the potential to become 
an antibiotic in high demand, particularly given its unique mechanism of action, 
which involves tight binding to the conserved peptidyl transferase centre, resistance to 
pleuromutilin is slow to be developed while it has minimal cross-resistance with other 
antibiotics (Davidovich et al., 2007; Paukner & Riedl, 2017). Conventional 
fermentation of pleuromutilin is not very efficient as the producing fungus is not very 
amenable to large-scale fermentation or to conventional strain improvement, so if it is 
to be produced in high-yield, a biotechnological solution to its production is needed. 
The pathway of pleuromutilin production has been identified by Bailey et al. (2016) 
and pathway intermediates have been elucidated by Alberti et al. (2017) by step-wise 
heterologous expression of the pathway genes in A. oryzae. The Alberti paper 
confirmed the expression of the partial pathway, where different intermediates could 
be isolated. These could be further chemically modified to obtain the end-metabolite. 
This approach also led to the development of bio-conversion chassis, as feeding 
chemically modified analogues could be converted to semi-synthetic pleuromutilin 
derivatives. Despite their work however, yields from heterologous production in a 
fungus were still comparatively low and so alternative expression platforms may be 
desirable. 
 This thesis explored the feasibility of producing pleuromutilins in bryophytes, 
showing that the host plants were tolerant to mutilin, the key precursor used in 
industry for conversion to medically relevant antibiotics. Plasmid vectors were made 
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to support expression of the necessary genes for expression of the biosynthetic 
pathway. Moss and liverwort hosts were screened for susceptibility to pleuromutilin. 
This work has shown that pleuromutilin, mutilin and a diverse selection of antibiotics 
impact on growth and development of P. patens and M. polymorpha, when 
supplemented into growing media. Interestingly, mutilin showed a 25- and a 10-fold 
antibiotic concentration tolerance of survival compared to tiamulin (pleuromutilin 
derivative) when tested in media growing P. patens or M. polymorpha, respectively. 
Both plant hosts also demonstrated some characteristic phenotypic changes when 
growing media were supplemented with some of the antibiotics under study, including 
mutilin for P. patens and tiamulin or mutilin for M. polymorpha. 
This project also consists of the first attempt of building the pleuromutilin 
pathway into different plant hosts. Initially, the multigene constructs used in 
transformation were made, consisting of the CaMV 35S promoter and nopaline 
synthase terminator. Successful transformants of M. polymorpha obtained geneticin-
resistant thalli, while plantlets transformed with the non-functional nptII selection 
marker plasmid became necrotic. Moreover, two out of eight Marchantia lines 
depicted the desirable peak of Rt 12.24 at 366 in the ES- spectrum in HPLC, 
indicating a possibility of mutilin production. Expression analysis was carried out to 
validate the heterologous expression of the genes. Whilst not definitive, these findings 
suggest that this might be a feasible approach for production if gene expression could 
be optimized. 
6.1 Antibiotic assays 
Subcellular organelles, such as mitochondria and chloroplasts are believed to 
have originated from endosymbiotic α-proteobacteria and cyanobacteria-like 
prokaryotes, respectively. However, in higher plants they are shown to have diverged 
142 
 
considerably from these ancestral origins, although bacteria-like ribosomes are 
present in both organelles (Kasten & Reski, 1997). Interestingly, inhibition of 
chloroplast division was observed in suspension cultures of P. patens but not in the 
dicot Lycopersicon esculentum (tomato) when treated with the β-lactam antibiotics 
ampicillin, cefotaxime and penicillin, and also led to macrochloroplast formation in P. 
patens. This study concluded that prokaryotes and moss chloroplasts may share a 
common component in their division mechanisms (Kasten & Reski, 1997). However, 
with moss chloroplasts lacking a peptidoglycan wall it is unclear how β-lactam 
antibiotics would act. In bacteria the penicillin-binding protein FtsI when binding to 
β-lactam antibiotics, cannot support FtsZ tubule formation, leading to undivided 
bacteria, and ,presumably, a FtsI homolog in moss could have a similar effect (Kasten 
& Reski, 1997; Miyagishima et al., 2014). Similarly, suspension cultures of M. 
polymorpha treated with the β-lactam antibiotic ampicillin were reported to show a 
decrease in chloroplast number, also demonstrating inhibition of chloroplast division 
(Tounou et al., 2002). There is a possibility that either the bacteria-like ribosomes, 
present in chloroplasts or mitochondria are responsible for the effect tiamulin 
(pleuromutilin derivative) has on growth and morphology of both P. patens and M. 
polymorpha. Support for this is the observation that mutilin showed a milder effect on 
growth and development of the two plant hosts. This is also seen in bacteria and is 
likely due to the role of the C-14 sidechain which is important for full activity, indeed 
this region is the part of the molecule that is then modified during semisynthesis to 
further improve the efficiency of derivatives such as Lefamulin. Whilst the 
susceptibility to pleuromutilin might prevent production of the mature compound in 
these plant hosts, the reduced susceptibility to mutilin might mean it is feasible to use 
such hosts to produce this pathway intermediate. 
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6.2 The suitability of the heterologous host 
In order to choose a plant host for heterologous expression of a desired 
compound, it should be taken into account whether the host is amenable to 
transformation and to be able to generate stable transformants in a reliable manner. 
Moreover, it is important that the host generates enough biomass to allow the desired 
production levels of the metabolite of interest. The endogenous flux of carbon through 
the pathway under study ought to be suitably high and flexible to provide any 
necessary precursors to the enzymes of the pathway. Last but not least, it is essential 
to eliminate the possibility of any endogenous enzymes modifying or metabolizing 
any intermediates or the final metabolite (Kempinski et al., 2015). While the first two 
criteria of amenability to transformation and generation of enough biomass can be 
predicted, the complexity of metabolic networks can presumably affect the stability of 
the precursors, the final metabolite, and/or the pathway enzymes in planta. 
Furthermore, how a multigene construct would interact with endogenous genetic 
circuits is unpredictable, requiring for multiple cycles of build-test-rebuild to fine-
tune the flux of the new pathway and eliminate any intermediates accumulation 
(Gandhi, 2019). Approaches that have been proposed for optimizing expression of 
multigene constructs consist of using tunable genetic filters (Deans et al., 2007; Wang 
et al., 2014), ribosome-binding site sequences (Salis et al., 2009), protein degradation-
targeting sequences (Cameron & Collins, 2014) and chemical inducers (Kelly et al., 
2016). 
6.3 Agrobacterium-infiltration of tobacco 
The chlorosis seen in tobacco with the 7-gene and 5-gene constructs suggests 
that the vectors may have worked, although with cell-death being a possible outcome 
of successful gene expression, regeneration of stable tobacco transformants would be 
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challenging. New peaks were seen in the HPLC traces from Agro-infiltrated extracts 
with a T-DNA of the empty vector, suggesting there was considerable stress after 
infiltration and no additional peaks were readily apparent with the 5- or 7-gene 
vectors. Even searches for compounds with specific masses failed to show any 
production. Such searches are very sensitive suggesting either the compounds were 
not produced, they were modified by the host or that they were bound to targets and 
so not available for extraction. Presence of chlorosis would support production having 
occurred but with detrimental effects on the host, so they may be toxic for tobacco, 
with the desired precursors probably being unstable in planta. 
6.4 M. polymorpha heterologous expression 
The initial attempts at transformation of Marchantia failed to yield any 
transformants however this was eventually shown to be because the L1 construct had 
the nptII ORF in the anti-sense orientation so should not lead to geneticin-resistant 
thalli. It should be noted that this would not have impacted on the Agrobacterium-
infiltration of tobacco discussed above, as kanamycin selection is not used during 
such infiltrations and the pleuromutilin transcriptional units should all still have been 
functional. Making the expression constructs with a corrected version of the L1 nptII 
was successful in generating geneticin-resistant transformants. Transformation of 
Marchantia is integrative and relatively low expression levels of the transgenes are 
reported to often be observed due to transgene silencing or positional effects, hence, it 
is recommended to analyze many independent lines (Kempinski et al., 2015). 
However time constraints due to Covid-19 limited the numbers of transformants that 
could be isolated and analysed. Furthermore, the repetitious use of the same promoter, 
as in this thesis, may lead to transcriptional gene silencing due to promoter 
methylation and thus inactivation. Solutions to this problem could be promoter 
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diversity, use of synthetic or chimeric promoters derived from conserved native ones, 
functional cis-elements of endogenous promoters or bidirectional promoters 
(Peremarti et al., 2010). Whilst this vector was designed and constructed, time 
constraints prevented its use in generating transformants. 
6.5 M. polymorpha HPLC analysis 
 Unfortunately, in none of the Group A or C transformants were there any 
peaks at the desired retention time (Rt), indicating that the specific intermediates were 
not produced. Given that the expression levels were so low when assessed by qPCR, 
the desired products might only be accumulated at low concentrations, hence the more 
sensitive technique of GCMS, appropriate for volatile diterpenes, could be used 
(Hamm et al., 2005). Very few transformants had detectable transcripts for all of the 
transgenes, so it may need a larger population of transformants to be assessed to 
identify those where production was possible. Alternatively it is possible that 
production was limited due to enzymes going to the wrong subcellular compartments. 
As reported by Ban et al., 2018, after heterologous expression of the secondary 
metabolite aphidocolin in A. oryzae, fusion with GFP of the geranygeranyl 
diphosphate synthase and terpene cyclase showed that they were localized in the 
cytoplasm, while P450s derived from Phoma betae were localized in the ER. Thus, 
aphidicolin production was almost completely lost in the PbP450-1 mutant lacking 
the transmembrane domain (Ban et al., 2018). Given the taxonomic distance between 
Marchantia and Clitopilus, it is possible that protein targeting sequences, if present, 
might not be functional, or that plant cytochrome P450 reductases might not 
reactivate fungal P450s in the case of the 7-gene transformants. 
 Two (B3, B4) out of eight lines of Group B (5-gene transformants) showed a 
peak at retention time (Rt) 12.24 with mass 366 in the ES- spectrum, demonstrating 
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the possibility of successful heterologous production of the precursor mutilin, 
although this was at very low levels. RNA expression levels of the genes of these 
samples showed that there is heterologous expression of all genes except for p450-1 
which might account for why mutilin yield was low. This is a promising result given 
how few transformants were analysed and that none showed strong expression of all 
the transgenes. 
6.6 Future work 
There are many directions this research could go in the future. Time constrains 
meant that comparatively few transformants were analysed in Marchantia, and that 
the “diverse promoters” construct was not evaluated. The analysis of more 
transformants, and possibility of elevated expression using the vector might support 
production of mutilin, even if pleuromutilin might not be possible due to toxicity. 
Similarly an initial aim was to duplicate this analysis in moss, and whilst plasmids 
were made for this, the transformation has not been tried. With a good-size population 
of transformants, RT-qPCR of the whole transcript of each gene would help identify 
those where all the genes were being efficiently expressed and help eliminate the 
probability of partial transcription, and thus no functional pathway. Time-permitting it 
would be interesting to use fluorescence fusion tags for real-time monitoring the 
destination of the pathway enzymes in planta, it might even be feasible to use the 
targeting sequences derived from plant diterpene biosynthesis proteins to help direct 
these fungal enzymes to the correct subcellular location for elevated antibiotic 
production.  
Despite these limitations, the hint of successful production of mutilin in 
Marchantia in this work is very positive and might open up the possibility of growing 
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Appendix A: Coding sequences of the genes after domestication and 
plasmid maps of Level 0, Level 1, Level 2 
 






































































































































































































































































Appendix B: Antibiotic treatments 
Antibiotic treatments for P. patens and M. polymorpha, at concentrations ranging from 1 
to 500μg/ml. Mock assays were treated using solvent (untreated). Each assay consisted of 2 or 3 
technical replicates. Scale bar is at 25mm. 
 
 
 
 
174 
 
 
 
 
 
 
 
175 
 
 
 
 
 
 
 
176 
 
 
 
 
 
 
177 
 
 
 
 
 
 
178 
 
 
 
